

- Sokol, F., Libikova, H., Zemla, J., 1959. Infectious ribonucleic acid from mouse brains infected with Tick-borne encephalitis virus. *Nature* 184 (Suppl. 20), 1581.
- Takashima, I., Morita, K., Chiba, M., Hayasaka, D., Sato, T., Takezawa, C., Igarashi, A., Kariwa, H., Yoshimatsu, K., Arikawa, J., Hashimoto, N., 1997. A case of Tick-borne encephalitis in Japan and isolation of the virus. *J. Clin. Microbiol.* 35 (8), 1943–1947.
- Vince, V., Grcevic, N., 1969. Development of morphological changes in experimental Tick-borne meningoencephalitis induced in white mice by different virus doses. *J. Neurol. Sci.* 9 (1), 109–130.
- Wang, Y., Lobigs, M., Lee, E., Koskinen, A., Mullbacher, A., 2006. CD8<sup>+</sup> T cell-mediated immune responses in West Nile virus (Saravend strain) encephalitis are independent of gamma interferon. *J. Gen. Virol.* 87 (Pt. 12), 3599–3609.
- Wang, Y., Lobigs, M., Lee, E., Mullbacher, A., 2003. CD8<sup>+</sup> T cells mediate recovery and immunopathology in West Nile virus encephalitis. *J. Virol.* 77 (24), 13323–13334.
- Yoshii, K., Konno, A., Goto, A., Nio, J., Obara, M., Ueki, T., Hayasaka, D., Mizutani, T., Kariwa, H., Takashima, I., 2004. Single point mutation in Tick-borne encephalitis virus prM protein induces a reduction of virus particle secretion. *J. Gen. Virol.* 85 (Pt. 10), 3049–3058.
- Zhao, Y., Ma, R., Shen, J., Su, H., Xing, D., Du, L., 2008. A mouse model of depression induced by repeated corticosterone injections. *Eur. J. Pharmacol.* 581 (1–2), 113–120.

# A Long-Term Survey on the Distribution of the Human Rotavirus G Type in Thailand

Yaowapa Pongsuwanna,<sup>1,2</sup> Ratigorn Guntapong,<sup>2</sup> Ratana Tacharoenmuang,<sup>2</sup> Malliga Prapanpoj,<sup>2</sup> Masanori Kameoka,<sup>1</sup> and Koki Taniguchi<sup>1,3\*</sup>

<sup>1</sup>Thailand-Japan Research Collaboration Center on Emerging and Re-emerging Infections (RCC-ERI), Nonthaburi, Thailand

<sup>2</sup>Department of Medical Sciences, National Institute of Health, Nonthaburi, Thailand

<sup>3</sup>Department of Virology and Parasitology, School of Medicine, Fujita Health University, Toyoake, Aichi, Japan

The distribution of the G type of human rotavirus was surveyed in Thailand between July 1993 and June 2007. A significant yearly change in the distribution of the G type distribution was found. From 1993–1994 to 1998–1999, the G1 type was the most dominant. In 1999–2000, G9 began to appear at a high frequency. In 2000–2001, 2001–2002, and 2002–2003, G9 was very common. In 2003–2004, G1 became the most prevalent type again, and since then it has been detected at the highest frequency. G12 strains, which were first detected in 1998–1999, were also found in 2004–2005 and 2006–2007. The G4 and G3 types were moderately prevalent in 2001–2002 and 2004–2005, respectively. Nucleotide sequence analysis of the VP7 genes of the G9 and G12 strains which reemerged in Thailand showed that they were each similar to the contemporary strains in other countries. *J. Med. Virol.* **82:157–163, 2010.** © 2009 Wiley-Liss, Inc.

**KEY WORDS:** rotavirus; G type; Thailand; sequence analysis; VP7

## INTRODUCTION

Group A human rotavirus is the most common etiologic agent of severe gastroenteritis in infants and young children worldwide. It has been estimated that all children will be infected at least once by the age of 5 years, and that rotavirus is responsible globally for ~600,000 deaths each year, mostly in developing countries [Parashar et al., 2006]. In both developed and developing countries, rotavirus infection leads to a high rate of hospital admission related to dehydration.

Rotaviruses possess a genome comprising 11 double-stranded RNA (dsRNA) segments, enclosed in a triple-layered protein capsid [Estes and Kapikian, 2007]. The outermost layer is composed of two proteins, VP7 and VP4, which are associated with the G type and P type, respectively. At least 15 different G types (G1–G15)

and 26 P types (P[1]–P[26]) have been found in humans and animals. Among them, 11 G types (G1–G6, G8–G11, and G12) and 10 P types (P[3]–P[6], P[8]–P[11], P[14], and P[19]) have been isolated from humans. The common G types worldwide are G1–G4, and G9 [Gentsch et al., 1996; Santos and Hoshino, 2005]. However, the distribution of the G type varies each year, and a distinct G type distribution has been found in different countries. Knowledge of the prevalence of the G type in each country has become more relevant, since two types of human rotavirus vaccine, RotaTeq (Merck & Co., Inc., Whitehouse Station, NJ) and Rotarix (GlaxoSmithKline Biologicals, Rixensart, Belgium), were developed in 2006 [Ruiz-Palacios et al., 2006; Vesikari et al., 2006]. The efficacy of both vaccines as to the heterotypic human rotaviruses in circulation is a serious concern. With this background, fundamental data on the distribution of the G type worldwide is important for the prevention of infection with human rotavirus. In many studies, however, surveys on the distribution of the G type have been carried out for a short-term or on small numbers of samples.

In this study, the yearly change of the distribution of the G type of human rotavirus was surveyed long-term and on a large-scale in Thailand between July 1993 and June 2007. Nucleotide sequence analyses of rotavirus strains with the G9 or G12 specificity, which were detected in this study are also described.

Grant sponsor: Ministry of Public Health, Thailand; Grant sponsor: Ministry of Education, Cultures, Sports, Science and Technology (MEXT) of Japan (partial support: Founding Research Center for Emerging and Reemerging Infectious Diseases).

\*Correspondence to: Koki Taniguchi, Department of Virology and Parasitology, School of Medicine, Fujita Health University, Toyoake, Aichi 470-1192, Japan. E-mail: kokitani@fujita-hu.ac.jp

Accepted 10 June 2009

DOI 10.1002/jmv.21596

Published online in Wiley InterScience  
(www.interscience.wiley.com)

## MATERIALS AND METHODS

### Stool Specimens and Study Sites

A total of 7,452 stool samples were collected from the same or different study sites in each period between July 1993 and June 2007 (1993–2007) in Thailand (Table I). In 1993–1994, 1,150 samples were collected from four hospitals: the Nakorn Ping Hospital in Chiang Mai, the Nakhon Phanom Hospital in Nakhon Phanom, the Children's Hospital in Bangkok, and the Hadyai Hospital in the Songkhla Province (near Malaysia), which are located in the northern, northeastern, central, and southern parts of Thailand, respectively. In 1994–1997 and 1999–2000, 359 samples were collected only from the Queen Sirikit National Institute of Child Health in Bangkok. In 1997–1999 and 2000–2001, 593 samples were collected from Nakhon Phanom. In 2001–2003, 2,153 samples were collected from six hospitals located throughout Thailand: the Maesod Hospital, Tak Province on the Myanmar border, the Nong Khai Hospital, Nong Khai Province on the Laos border, Chantaburi Hospital, Chanthaburi Province near the Cambodia border, Sa Kaeo Hospital, Sa Kaeo Province on the Cambodia border, and Hadyai Hospital. Between July 2003 and June 2007, 3,197 stool specimens were examined at three or four study sites: the Maesod Hospital, the Nong Khai Hospital, the Chanthaburi Hospital, and the Hadyai Hospital.

### Detection of Rotavirus

All stool specimens were screened for rotavirus by polyacrylamide gel electrophoresis (PAGE) of the segmented rotaviral genome as described previously [Pongsuwanna et al., 1996], since non-group A rotaviruses and picobirnaviruses can also be detected by this method, although PAGE of RNA exhibits relatively low sensitivity. In brief, rotaviral RNA was extracted from stool specimens with a disruption solution comprising sodium dodecyl sulfate (SDS), 2-mercaptoethanol, and EDTA, and then with phenol–chloroform. The RNA was electrophoresed on 10% acrylamide gels (2-mm thick) for 16 hr at 20 mA at room temperature. RNA segments were visualized by silver staining.

### RT-PCR

PCR-typing was undertaken in two steps (first and second amplifications) as described previously [Gouvea et al., 1990; Taniguchi et al., 1992]. In the first amplification, complementary DNA corresponding to the full-length VP7 gene was amplified with a pair of primers for the 3' and 5' ends of VP7 genes. The second amplification was carried out using a mixture of primers that are specific to each of six variable regions of the VP7 genes of G1–4, G8, and G9 paired with a primer for the 3' end of the VP7 gene.

### Nucleotide Sequence Determination

Full-length cDNAs of the VP7 genes of 16 G9 strains and 7 G12 strains were prepared by RT-PCR. Direct

sequencing was carried out using the ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction kits (AB Applied Biosystems, Foster City, CA) with an automated sequencer, an ABI Prism 3100 Genetic Analyzer (AB Applied Biosystems). Nucleotide sequences were analyzed for the construction of phylogenetic trees using Clustal W 1.8.

### Nucleotide Sequence Accession Numbers

The nucleotide sequence data described in this article for the VP7 genes of Thai rotavirus strains were submitted to the GenBank database and have been assigned the accession numbers: AB436813 (G12 strain MS064-05), AB436814 (G12 strain MS310-06), AB436815 (G12 strain MS329-06), AB436816 (G12 strain MS038-07), AB436817 (G12 strain MS040-07), AB436818 (G12 strain MS041-07), AB436819 (G12 strain MS051-07), AB436820 (G9 strain HRV-205-99), AB436821 (G9 strain HRV00-01), AB436822 (G9 strain HY006-01), AB436823 (G9 strain CHB010-01), AB436824 (G9 strain NK002-01), AB436825 (G9 strain MS057-02), AB436826 (G9 strain HY070-02), AB436827 (G9 strain SK066-02), AB436828 (G9 strain NK018-02), AB436829 (G9 strain CHB058-02), AB436830 (G9 strain HY095-03), AB436831 (G9 strain MS037-03), AB436832 (G9 strain SK041-03), AB436833 (G9 strain NK022-03), AB436834 (G9 strain CHB002-04), and AB436835 (G9 strain NK008-04).

## RESULTS

### Detection of Rotavirus

Of the 7,452 stool specimens screened for rotavirus RNA by PAGE, 2,560 (34.4%) were positive for rotavirus (Table I). The survey of the G type distribution in Thailand since 1988 showed that the incidence of rotavirus was high between September and February, particularly in November, December, and January, the coldest months of the year in Thailand, and that there were few incidences of rotavirus infection in June and July (data not shown), and therefore the year between July of a given year and the next June was considered as one rotavirus season. For example, 1993–1994 means the year between July 1993 and June 1994.

### Distribution of the G Type

In the survey between July 1993 and June 2007, G1 (47.0%) was overall the most dominant G type in Thailand, followed by G9 (22.6%), G2 (9.1%), and G4 (3.5%) (Table I). G1 was the most prevalent from 1993–1994 to 1998–1999 and from 2003–2004 to 2006–2007. G9 appeared in 1999–2000 at a high frequency, and was the most prevalent in 2000–2001, 2001–2002, and 2002–2003, the prevalence rates being 79.2%, 82.6%, and 49.1%, respectively. In 2002–2003, G2 was highly prevalent type (35.8%). G3 was rare in Thailand throughout the years studied, but G3 was a highly prevalent (22.0%) in 2004–2005. G4 showed a high prevalence only in 2001–2002. A very unusual G8 strain was

TABLE I. G Type Distribution of Human Rotavirus in Thailand Between July 1993 and July 2007

Collection year	Collection sites	No. of specimens collected	No. of specimens positive for rotavirus (positive rate %)	G type (%)										Not determined
				G1	G2	G3	G4	G8	G9	G12				
1993-1994	<b>Total</b>	<b>1,150</b>	<b>368 (32.0)</b>	<b>316 (85.9)</b>	<b>7 (1.9)</b>	<b>0</b>	<b>11 (3.0)</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>34 (9.2)</b>	
	Bangkok	414	125 (30.2)	116 (92.8)	0	2 (1.8)	0	0	0	0	0	0	7 (5.6)	
	Chiang Mai	200	54 (27.0)	44 (81.5)	5 (9.3)	0	0	0	0	0	0	0	5 (9.3)	
	Nakorn Panom	119	37 (31.1)	35 (94.6)	0	2 (5.4)	0	0	0	0	0	0	0	
	Songkhla	417	152 (36.5)	121 (79.6)	2 (1.3)	7 (4.6)	0	0	0	0	0	0	22 (14.5)	
1994-1995	<b>Total</b>	<b>163</b>	<b>99 (60.7)</b>	<b>79 (79.8)</b>	<b>4 (4.0)</b>	<b>0</b>	<b>4 (4.0)</b>	<b>0</b>	<b>0</b>	<b>1 (1.0)</b>	<b>0</b>	<b>0</b>	<b>11 (11.1)</b>	
	Bangkok	47	31 (66.0)	26 (83.9)	4 (12.9)	0	1 (3.2)	0	0	0	0	0	0	
	Bangkok	113	51 (45.1)	32 (62.8)	9 (17.6)	0	0	3 (5.9)	0	0	0	0	7 (13.7)	
	Nakorn Panom	147	29 (19.7)	1 (3.4)	0	0	0	0	0	0	0	0	2 (6.9)	
	Nakorn Panom	262	101 (38.5)	91 (90.1)	2 (2.0)	0	0	0	0	0	0	1 (1.0)	7 (6.9)	
1998-1999	<b>Total</b>	<b>36</b>	<b>14 (38.9)</b>	<b>1 (7.1)</b>	<b>6 (42.9)</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>2 (14.3)</b>	
	Bangkok	184	53 (28.8)	3 (5.7)	0	1 (1.9)	3 (5.7)	0	42 (79.2)	0	0	0	4 (7.6)	
	Nakorn Panom	1,061	356 (33.6)	4 (1.1)	0	1 (0.3)	57 (16.0)	0	294 (82.6)	0	0	0	0	
	Nong Khai	156	62 (39.7)	0	0	0	1 (0.6)	0	61 (98.4)	0	0	0	0	
	Chanthaburi	242	73 (30.2)	2 (2.7)	0	0	9 (12.3)	0	62 (84.9)	0	0	0	0	
2000-2001	<b>Total</b>	<b>271</b>	<b>84 (31.0)</b>	<b>2 (2.4)</b>	<b>0</b>	<b>1 (1.2)</b>	<b>18 (21.4)</b>	<b>0</b>	<b>63 (75.0)</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	
	Tak	235	80 (34.0)	0	0	0	29 (36.3)	0	51 (63.8)	0	0	0	0	
	Sa Kaeo	157	57 (36.3)	0	0	0	0	0	57 (100.0)	0	0	0	0	
	Nong Khai	250	107 (42.8)	0	0	0	2 (0.5)	0	210 (49.1)	0	0	0	61 (14.3)	
	Chanthaburi	164	59 (36.0)	1 (1.7)	9 (8.4)	0	2 (1.9)	0	78 (72.9)	0	0	0	18 (16.8)	
2002-2003	<b>Total</b>	<b>1,092</b>	<b>428 (39.2)</b>	<b>1 (2.0)</b>	<b>36 (72.0)</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>21 (35.6)</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>15 (25.4)</b>	
	Tak	143	50 (35.0)	1 (2.0)	0	0	0	0	5 (10.0)	0	0	0	8 (16.0)	
	Songkhla	343	131 (38.2)	0	16 (12.2)	0	0	0	105 (80.2)	0	0	0	10 (7.6)	
	Sa Kaeo	192	81 (42.2)	0	70 (86.4)	0	0	0	1 (1.2)	0	0	0	10 (12.3)	
	Nong Khai	543	174 (32.0)	107 (61.5)	14 (8.1)	0	6 (3.5)	1 (0.6)	18 (10.3)	0	0	0	28 (16.1)	
2003-2004	<b>Total</b>	<b>156</b>	<b>47 (30.1)</b>	<b>30 (63.8)</b>	<b>4 (8.5)</b>	<b>0</b>	<b>1 (2.1)</b>	<b>6 (12.8)</b>	<b>8 (18.6)</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>6 (12.8)</b>	
	Nong Khai	207	72 (34.8)	43 (59.7)	8 (18.6)	0	5 (11.6)	0	8 (18.6)	0	0	0	8 (18.6)	
	Chanthaburi	155	47 (30.3)	34 (72.3)	0	0	0	0	0	0	0	0	13 (27.7)	
	Tak	25	8 (32.0)	0	2 (25.0)	0	0	0	4 (50.0)	0	0	0	1 (12.5)	
	Songkhla	422	109 (25.8)	36 (33.0)	5 (4.6)	24 (22.0)	2 (1.8)	0	2 (1.8)	2 (1.8)	0	0	38 (34.9)	
2004-2005	<b>Total</b>	<b>119</b>	<b>49 (41.2)</b>	<b>13 (26.5)</b>	<b>0</b>	<b>8 (16.3)</b>	<b>0</b>	<b>0</b>	<b>1 (2.0)</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>27 (55.1)</b>	
	Nong Khai	164	21 (12.8)	18 (85.7)	3 (14.3)	0	0	0	0	0	0	0	0	
	Chanthaburi	139	39 (28.1)	5 (12.8)	2 (5.1)	16 (41.0)	2 (5.1)	0	1 (2.6)	2 (5.1)	0	0	11 (28.2)	
	Tak	1,105	428 (38.7)	361 (84.4)	6 (1.4)	6 (1.4)	0	0	5 (1.2)	0	0	0	50 (11.7)	
	Songkhla	141	55 (39.0)	52 (94.5)	0	0	0	0	0	0	0	0	3 (5.5)	
2005-2006	<b>Total</b>	<b>569</b>	<b>273 (48.0)</b>	<b>233 (85.3)</b>	<b>5 (1.8)</b>	<b>1 (0.4)</b>	<b>0</b>	<b>0</b>	<b>3 (1.1)</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>31 (11.4)</b>	
	Nong Khai	202	63 (31.2)	45 (71.4)	1 (1.6)	5 (7.9)	0	0	0	0	0	0	12 (19.0)	
	Chanthaburi	193	37 (19.2)	31 (83.8)	0	0	0	0	0	0	0	0	4 (10.8)	
	Tak	1,127	289 (25.6)	120 (41.5)	21 (7.2)	6 (2.1)	0	0	2 (0.1)	2 (0.1)	0	0	134 (46.4)	
	Songkhla	136	16 (11.8)	14 (87.5)	0	0	0	0	0	0	0	0	2 (12.5)	
2006-2007	<b>Total</b>	<b>520</b>	<b>127 (24.4)</b>	<b>61 (48.0)</b>	<b>16 (12.6)</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>50 (39.4)</b>	
	Nong Khai	348	128 (37.3)	34 (26.6)	5 (3.9)	6 (4.7)	0	0	2 (1.6)	6 (4.7)	0	0	75 (58.6)	
	Chanthaburi	128	18 (14.1)	11 (61.1)	0	0	0	0	0	0	0	0	7 (38.9)	
	Tak	7,452	2,560 (34.4)	1,204 (47.0)	232 (9.1)	38 (1.5)	89 (3.5)	1 (0.04)	579 (22.6)	9 (0.4)	0	0	378 (14.8)	
	Songkhla													

Rotavirus was detected by PAGE analysis of RNA, and the G type was determined by RT-PCR. Data as a total in each collection year are shown in bold.

detected in 2003–2004. G12 (strain T152) was first detected in Thailand in 1998–1999 [Pongsuwanna et al., 2002]. G12 strains were also found in 2004–2005 and 2006–2007, although the incidence was low. Although strain T152 was detected in the Children's Hospital in Bangkok, the G12 strains detected after 2004 were all in the Maesod Hospital, Tak Province (Myanmar border). Thus, a drastic yearly change in the G type distribution was observed in Thailand in 1993–2007. It was of note that G9 and G12 rotaviruses had reemerged in Thailand.

The trend of the changes in the distribution of the G type in different regions of Thailand was almost the same. However, there were also some differences in the distribution of the G type depending on the regions where collections were undertaken, for example, G2 was highly prevalent in the Tak and Sa Kaeo regions in 2002–2003 compared to the other regions, and the prevalence of G3 was much higher in the Tak region than in the other regions in 2004–2005 (Table I).

### Sequence Analysis of G9 Human Rotaviruses

In order to characterize the G9 strains that reemerged in Thailand, the complete nucleotide sequences of the VP7 genes of 16 representative G9 strains collected in four different districts and different years in this study were determined, the sequences being compared with each other and with those of the representative G9 strains detected in Thailand and other countries. The identity was very high among the 16 Thai G9 strains detected between 1999 and 2004 in this study: 99.1–99.9% at the nucleotide level and 98.2–100.0% at the amino acid level. On comparison with Thai G9 strains in other studies, the 16 present Thai G9 strains showed identities of 99.4–99.6%, 98.0–98.2%, and 95.0–95.2% at the nucleotide level with strains CMH319Thai and CMH045Thai detected in 2000–2001, 97CM86 in 1997, and Mc345 in 1988, respectively. It has been shown that there are three lineages (I–III) of G9 strains on phylogenetic analysis [Hoshino et al., 2004]: I comprises prototypes WI61, F45, and AU32; II comprises strain 116E; and III comprises the G9 strains that reemerged. The Thai 16 G9 strains that reemerged in Thailand are also included in lineage III (Fig. 1).

### Sequence Analysis of G12 Human Rotavirus

The RNA profiles of the seven Thai G12 strains were examined by PAGE. They all exhibited similar RNA patterns (Fig. 2). The complete VP7 nucleotide sequences of the seven G12 strains detected in 2004–2005 and 2006–2007 were also determined. The VP7 nucleotide sequences of the seven Thai G12 strains showed very high identities (99.3–100%). In contrast, they exhibited 90.2–90.4% identity to prototype strain L26, 90–90.2% to porcine RU172 strain, 97.2–97.6% to a Thai strain, T152, detected in 1998–1999, and 97.7–98.5% to the G12 strains that reemerged in other countries. On phylogenetic analysis, the seven Thai G12 strains were found to be closely related to the strains




Fig. 1. Phylogenetic analysis of nucleotide sequences of the full VP7 genes of human G9 rotavirus strains detected in Thailand. The strain names with asterisks are those detected in this study. Reference sequences were obtained from the GenBank and EMBL databases. The bar indicates the variation scale.

detected after 2000 and thus were included in lineage III (Fig. 3).

## DISCUSSION

In Thailand, diarrhea remains an important cause of morbidity and mortality among infants and young children, and rotavirus infection is a common cause of hospital admission [Pipittajan et al., 1991; Maneekarn and Ushijima, 2000; Bresee et al., 2004; Veeravigrom et al., 2004; Jiraphongsa et al., 2005; Sungkapalee et al., 2006]. It has been estimated that in Thai patients with diarrhea, the risks of rotavirus diarrhea, of a health care visit, and of hospital admission are 1 in 8, 1 in 36, and 1 in 85, respectively [Jiraphongsa et al., 2005]. The occurrence of rotavirus diarrhea in Thailand has a unimodal distribution pattern with a peak in October through to February [Jiraphongsa et al., 2005; data not shown], and rotavirus infection was found most frequently in children aged 6–11 months up to 2 years (data not shown).

In Thailand, a number of interesting epidemiological features were revealed by continuous surveys of




Fig. 2. RNA profiles of human G12 rotavirus strains detected in Thailand.

gastroenteritis virus among humans and animals: (1) unusual G10 human and porcine rotaviruses were detected [Pongsuwanna et al., 1996], (2) various combinations of G type and P type of bovine rotaviruses were found [Taniguchi et al., 1991], (3) a G12 human rotavirus with P[9] specificity was detected [Pongsuwanna et al., 2002], (4) group B and C porcine rotaviruses were detected [Pongsuwanna et al., 1996; unpublished data], and (5) picobirnaviruses were detected in pigs and humans [Pongsuwanna et al., 1996; Wakuda et al., 2005].

Regarding the G type distribution in Thailand, a yearly change in the distribution of the G type was also found in previous studies [Pongsuwanna et al., 1989, 1993]. In 1988–1989, 1989–1990, and 1991–1992, G1 was most prevalent. In 1990–1991 and 1992–1993, G3 and G2 were predominant, respectively. Thus, following the previous studies, a 19-year survey of the distribution of the G type in Thailand was carried out. Such a long-term survey in the same country will be useful for understanding the epidemiology of human rotavirus, and will provide fundamental data useful for future introduction of rotavirus vaccines.

Other studies on the distribution of G type studies have been performed in Thailand. In Chiang Mai between 1995 and 1997, G1, G2, G4, and G9 were detected at frequencies of 47%, 40%, 3%, and 6%, respectively, and G9 was found to have reemerged in 1996–1997 in Thailand [Zhou et al., 2001]. In the present study, interestingly, G9 rotavirus was detected earlier and in 1994–1995. However, the genome could not be characterized because the stool sample is not available now. In Bangkok, Thailand, between November 2002 and March 2004, the G types of 36 rotavirus-positive specimens




Fig. 3. Phylogenetic analysis of nucleotide sequences of the full VP7 genes of human G12 rotavirus strains detected in Thailand. The strain names with asterisks are those detected in this study. Reference sequences were obtained from the GenBank and EMBL databases. The bar indicates the variation scale.

were determined. Types G1, G2, and G9 were detected in 5.6%, 69.4%, and 25.0%, respectively [Theamboonlers et al., 2005]. In 2000–2001, 107 samples were subjected to G type determination: G9 was the most prevalent (91.6%), followed by G3 (5.6%) and G2 (2.8%) in Chiang Mai [Khamrin et al., 2006]. In 2003 and 2004, G2 and G1 were identified as the most dominant types, respectively [Khamrin et al., 2007]. The present long-term and large-scale study extended these small-scale studies and strengthened the data.

A changing distribution of rotavirus G types has been reported in other countries, although some differences

were observed. In Australia, G1 was the most prevalent in 1999–2001, G9 was highly prevalent in 2001–2003, and G1 was again the most prevalent type after 2004 [O’Ryan, 2009]. In Italy, G1 was highly prevalent in 2001, 2002, and 2004, and G9 was the most common type in 2005 [De Grazia et al., 2007]. In Ireland, G9 was the most prevalent type in 2001–2002, and G1 was identified as the most common G type in 2002–2004 [Reidy et al., 2005].

G9 rotavirus was first isolated in the United States in 1983 and then in Japan in 1985. After that, G9 rotaviruses were not detected for about a decade but reemerged in the mid-1990s. The G9 strains that reemerged were distinct genetically from those in the 1980s. At present, G9 rotaviruses have emerged as the fifth most common G type worldwide [Ramachandran et al., 2000; Santos and Hoshino, 2005]. Therefore, it has been suggested that G9 should be incorporated into candidate rotavirus vaccines [Montenegro et al., 2007]. At least three phylogenetic sequence lineages have been reported among the VP7 nucleotides of G9 rotaviruses [Hoshino et al., 2004]. Lineage 1 includes those isolated in the 1980s, lineage 2 G9 strains have been detected only in asymptomatic neonates in India, and the majority of G9 strains that are prevalent around the world today belong to lineage 3. The VP7 genes of the Thai G9 strains detected in this study were found to have very similar nucleotide and amino acid sequences, and were closely related to lineage 3 G9 strains.

G12 was first identified and characterized in 1990 among rotaviruses causing diarrhea in children in the Philippines [Taniguchi et al., 1990; Urasawa et al., 1990]. After a long period, the G12 strains have reemerged in Thailand [Pongsuwanna et al., 2002; Wakuda et al., 2003], the United States [Griffin et al., 2002], Japan [Shinozaki et al., 2004], Argentina [Castello et al., 2006], Nepal [Uchida et al., 2006], India [Ray et al., 2007], Bangladesh [Rahman et al., 2007], Belgium [Rahman et al., 2007], Slovenia [Steyer et al., 2007], South Korea [Le et al., 2008], Saudi Arabia [Kheyami et al., 2008], South Africa [Page et al., 2009], Hungary [Banyai et al., 2009], and Malawi [Cunliffe et al., 2009]. One porcine G12 virus was also detected in India [Ghosh et al., 2006]. A high incidence has been reported in several countries such as Nepal. There is a possibility that extensive spread of the G12 type at high frequency has occurred, as found for G9. Using phylogenetic analysis, G12 strains are grouped into four lineages: lineage I includes prototype strain L26; lineage II consists of strains from Thailand (strain T152), Japan and Argentina; lineage III includes the US strain, and most Indian and Bangladesh strains; and lineage IV comprises only a porcine strain, RU172 [Rahman et al., 2007]. Following the detection of G12 strain T152 in Thailand in 1998–1999, the G12 rotavirus was detected in this Thai study in 2004–2005 and 2006–2007. Differing from strain T152 detected in 1998–1999, the seven Thai G12 strains detected in 2004–2005 and 2006–2007 are included in lineage III. These results indicate that G12 rotavirus is now endemic in Thailand. However, the G12

strains were detected in the same district in different years, and they showed almost the same RNA profiles. This indicates that the G12 strains have not spread throughout Thailand. It is of interest to follow the spread of G12 rotavirus strains in Thailand.

The distribution of the G type in Thailand has changed with time. Continuous monitoring of epidemiology of rotavirus is important, especially for the introduction of a vaccine, in order to document its impact and to ensure its continued effectiveness. Comprehensive analysis of the diversity of rotavirus may have significant implications for the development and implementation of an effective rotavirus vaccine of the next generation. Analysis of the P type and other segments is required for more precise characterization.

#### ACKNOWLEDGMENTS

We thank Dr. Pathom Sawanpanyalert and Dr. Yoshitake Nishimune for their encouragement and valuable discussions regarding this study.

#### REFERENCES


- Banyai K, Bogdan A, Domonkos G, Kisfali P, Molnar P, Toth A, Melegh B, Martella V, Gentsch JR, Szucs G. 2009. Genetic diversity and zoonotic potential of human rotavirus strains, 2003–2006, Hungary. *J Med Virol* 81:362–370.
- Bresee J, Fang Z-Y, Wang B, Nelson EAS, Tam J, Soenarto Y, Wilpo SA, Kilgore P, Kim JS, Kang JO, Lan WS, Gaik CL, Moe K, Chen K-T, Jiraphongsa C, Pongsuwanna Y, Man NV, Tu PV, Luan LT, Hummelman E, Gentsch JR, Glass R. the members of the Asian Rotavirus Surveillance Network. 2004. First report from the Asian rotavirus surveillance network. *Emerg Infect Dis* 10:988–995.
- Castello AA, Arguelles MH, Rota RP, Olthoff A, Jiang B, Glass RI, Gentsch JR, Glikmann G. 2006. Molecular epidemiology of group A rotavirus diarrhea among children in Buenos Aires, Argentina, from 1999 to 2003 and emergence of the infrequent genotype G12. *J Clin Microbiol* 44:2046–2050.
- Cunliffe NA, Ngwira BM, Dove W, Nakagomi O, Nakagomi T, Perez A, Hart CA, Kazembe PN, Mwansambo CC. 2009. Serotype g12 rotaviruses, Lilongwe, Malawi. *Emerg Infect Dis* 15:87–90.
- De Grazia S, Ramirez S, Giammanco GM, Colomba C, Martella V, Lo Biundo C, Mazzola R, Arista S. 2007. Diversity of human rotaviruses detected in Sicily, Italy, over a 5-year period (2001–2005). *Arch Virol* 152:833–837.
- Estes MK, Kapikian AZ. 2007. Rotaviruses and their replication. In: Fields BN, Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, editors. *Fields virology*. 5th edition. Philadelphia, PA: Lippincott, Williams and Wilkin. pp 1917–1974.
- Gentsch JR, Woods PA, Ramachandran M, Das BK, Leite JP, Alfieri A, Kumar R, Bhan MK, Glass RI. 1996. Review of G and P typing results from a global collection of rotavirus strains: Implications for vaccine development. *J Infect Dis* 174:S30–S36.
- Ghosh S, Varqese V, Samajdar S, Bhattacharya SK, Kobayashi N, Naik TL. 2006. Molecular characterization of a porcine group A rotavirus strain with G12 genotype specificity. *Arch Virol* 151:1329–1344.
- Gouvea V, Glass RI, Woods P, Taniguchi K, Clark HF, Forrester B, Fang ZY. 1990. Polymerase chain reaction amplification and typing of rotavirus nucleic acid from stool specimens. *J Clin Microbiol* 28:276–282.
- Griffin DD, Nakagomi T, Hoshino Y, Nakagomi O, Kirkwood CD, Parashar UD, Glass RI, Gentsch JR, National Rotavirus Surveillance System. 2002. Characterization of nontypeable rotavirus strains from the United States: Identification of a new rotavirus reassortant (P2A[6], G12) and rare P3[9] strains related to bovine rotaviruses. *Virology* 294:256–269.
- Hoshino Y, Jones RW, Ross J, Honma S, Santos N, Gentsch JR, Kapikian AZ. 2004. Rotavirus serotype G9 strains belonging to VP7 gene phylogenetic sequence lineage 1 may be more suitable for

- serotype G9 vaccine candidates than those belonging to lineage 2 or 3. *J Virol* 78:7795–7802.
- Jiraphongsa C, Bresee JS, Pongsuwanna Y, Kluabwang P, Poonawagul U, Arpornit P, Kanoksil M, Prensri N, Intusoma U, for the Rotavirus Surveillance Project Thailand Study Group. 2005. Epidemiology and burden of rotavirus diarrhea in Thailand: Results of sentinel surveillance. *J Infect Dis* 192:S87–S93.
- Khamrin P, Peerakome S, Wongsawasdi L, Tonusin S, Sornchai P, Maneerat V, Khamwan C, Yagyu F, Okitsu S, Ushijima H, Maneekarn N. 2006. Emergence of human G9 rotavirus with an exceptionally high frequency in children admitted to hospital with diarrhea in Chiang Mai, Thailand. *J Med Virol* 78:273–280.
- Khamrin P, Peerakome S, Tonusin S, Malasao R, Okitsu S, Mizuguchi M, Ushijima H, Maneekarn N. 2007. Changing pattern of rotavirus G genotype distribution in Chiang Mai, Thailand from 2002 to 2004: Decline of G9 and reemergence of G1 and G2. *J Med Virol* 79:1775–1782.
- Kheyami AM, Nakagomi T, Nakagomi O, Dove W, Hart CA, Cunliffe NA. 2008. Molecular epidemiology of rotavirus diarrhea among children in Saudi Arabia: First detection of G9 and G12 strains. *J Clin Microbiol* 46:1185–1191.
- Le VP, Kim JY, Cho SL, Nam SW, Lim I, Lee HJ, Kim K, Chung SI, Song W, Lee KM, Rhee MS, Lee JS, Kim W. 2008. Detection of unusual rotavirus genotypes G8P[8] and G12P[6] in South Korea. *J Med Virol* 80:175–182.
- Maneekarn N, Ushijima H. 2000. Epidemiology of rotavirus infection in Thailand. *Pediatr Int* 42:415–421.
- Montenegro FM, Correia JB, Rodrigues FA, Dove W, Nakagomi T, Nakagomi O, Cuevas LE. 2007. Anticipating rotavirus vaccines in Brazil: Detection and molecular characterization of emerging rotavirus serotypes G8 and G9 among children with diarrhea in Recife, Brazil. *J Med Virol* 79:335–340.
- O’Ryan M. 2009. The ever-changing landscape of rotavirus serotypes. *Pediatr Infect Dis J* 28:S60–S62.
- Page NA, de Beer MC, Seheri LM, Dewar JB, Steele AD. 2009. The detection and molecular characterization of human G12 genotypes in South Africa. *J Med Virol* 81:106–113.
- Parashar UD, Hummelman EG, Bresee JS, Glass RI. 2006. Rotavirus and severe childhood diarrhea. *Emerg Infect Dis* 12:304–306.
- Pipittajan P, Kasempimolporn S, Ikegami N, Akatani K, Wasi C, Sinarachatanant P. 1991. Molecular epidemiology of rotaviruses associated with pediatric diarrhea in Bangkok, Thailand. *J Clin Microbiol* 29:617–624.
- Pongsuwanna Y, Taniguchi K, Choonthanom N, Chiwakul M, Susansook T, Saguanwongse S, Jayavasu C, Urasawa S. 1989. Subgroup and serotype distribution of human, bovine, and porcine rotavirus in Thailand. *J Clin Microbiol* 27:1956–1960.
- Pongsuwanna Y, Taniguchi K, Wakasugi F, Sutivijit Y, Chiwakul M, Wrachit P, Jayavasu C, Urasawa S. 1993. Distinct yearly change of serotype distribution of human rotavirus in Thailand as determined by ELISA and PCR. *Epidemiol Infect* 111:407–412.
- Pongsuwanna Y, Taniguchi K, Chiwakul M, Urasawa T, Wakasugi F, Jayavasu C, Urasawa S. 1996. Serological and genomic characterization of porcine rotaviruses in Thailand: Detection of a G10 porcine rotavirus. *J Clin Microbiol* 34:1050–1057.
- Pongsuwanna Y, Guntapong R, Chiwakul M, Tacharoenmuang R, Onvimala N, Wakuda M, Kobayashi N, Taniguchi K. 2002. Detection of a human rotavirus with G12 and P[9] specificity in Thailand. *J Clin Microbiol* 40:1390–1394.
- Rahman M, Matthijnsens J, Yang X, Delbeke T, Arijs I, Taniguchi K, Iturriza-Gomara M, Iftekaruddin N, Azim T, Van Ranst M. 2007. Evolutionary history and global spread of the emerging G12 human rotaviruses. *J Virol* 81:2382–2390.
- Ramachandran M, Kirkwood CD, Unicomb L, Cunliffe NA, Ward RL, Bhan MK, Clark HF, Glass RI, Gentsch JR. 2000. Molecular characterization of serotype G9 rotavirus strains from a global collection. *Virology* 278:436–444.
- Ray P, Sharma S, Agarwal RK, Longmei K, Gentsch JR, Paul VK, Glass RI, Bhan MK. 2007. First detection of G12 rotaviruses in newborns with neonatal rotavirus infection at All India Institute of Medical Sciences, New Delhi, India. *J Clin Microbiol* 45:3824–3827.
- Reidy N, O’Halloran F, Fanning S, Cryan B, O’Shea H. 2005. Emergence of G3 and G9 rotavirus and increased incidence of mixed infections in the Southern region of Ireland 2001–2004. *J Med Virol* 77:571–578.
- Ruiz-Palacios GM, Pérez-Schael I, Velázquez FR, Abate H, Breuer T, Clemens SC, Chevart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, López P, Macías-Parra M, Ortega-Barría E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavia-Ruz N, Salmerón J, Rüttimeann R, Tinoco JC, Rubio P, Nuñez E, Guerrero ML, Yarzabal JP, Damaso S, Tornieporth N, Sáez-Llorens X, Vergara RF, Vesikari T, Bouckennooghe A, Clemens R, De Vos B, O’Ryan M. 2006. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. *N Engl J Med* 354:11–22.
- Santos N, Hoshino Y. 2005. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. *Rev Med Virol* 15:29–56.
- Shinozaki K, Okada M, Nagashima S, Kaiho I, Taniguchi K. 2004. Characterization of human rotavirus strains with G12 and P[9] detected in Japan. *J Med Virol* 73:612–616.
- Steyer A, Poljsak-Prijatelj M, Bufon TL, Marcun-Varda N, Marin J. 2007. Rotavirus genotypes in Slovenia: Unexpected detection of G8P[8] and G12P[8] genotypes. *J Med Virol* 79:626–632.
- Sungkapalee T, Puntukosit P, Eunsuwan O, Theamboonlers A, Chongsrisawat V, Poovorawan Y. 2006. Incidence and clinical manifestations of rotavirus infection among children with acute diarrhea admitted at Buri Ram Hospital, Thailand. *Southeast Asian J Trop Med Public Health* 37:1125–1131.
- Taniguchi K, Urasawa T, Kobayashi N, Gorziglia M, Urasawa S. 1990. Nucleotide sequence of VP4 and VP7 genes of human rotaviruses with subgroup I specificity and long RNA pattern: Implication of new G serotype specificity. *J Virol* 64:5640–5644.
- Taniguchi K, Urasawa T, Pongsuwanna Y, Choonthanom M, Jayavasu C, Urasawa S. 1991. Molecular and antigenic characterization of serotypes 8 and 10 of bovine rotaviruses in Thailand. *J Gen Virol* 72:2929–2937.
- Taniguchi K, Wakasugi F, Pongsuwanna Y, Urasawa T, Ukae S, Chiba S, Urasawa S. 1992. Identification of human and bovine rotavirus serotypes by polymerase chain reaction. *Epidemiol Infect* 109:303–312.
- Theamboonlers A, Veravigrong N, Yambangyang O, Trairatvorakul P, Chongsrisawat V, Poovorawan Y. 2005. The incidence of rotavirus A isolates of G genotype in Thailand in 2002–2004. *Acta Virol* 49:111–115.
- Uchida R, Pandey BD, Sherchand SB, Ahmed K, Yokoo M, Nakagomi T, Cuevas LE, Cunliffe NA, Hart CA, Nakagomi O. 2006. Molecular epidemiology of rotavirus diarrhea among children and adults in Nepal: Detection of G12 strains with P[6] or P[8] and a G11P[25] strain. *J Clin Microbiol* 44:3499–3505.
- Urasawa T, Urasawa S, Wakasugi F, Kobayashi N, Taniguchi K, Lintag IC, Sanil MC, Goto H. 1990. Presumptive seventh serotype of human rotavirus. *Arch Virol* 113:279–282.
- Veeravigrong M, Theamboonlers A, Poovorawan Y. 2004. Epidemiology and clinical manifestation of rotavirus and Norwalk-like viruses in Thai children. *J Med Assoc Thai* 87:S50–S54.
- Vesikari T, Clark HF, Offit PA, Dallas MJ, DiStefano DJ, Goveia MG, Ward RL, Schödel F, Karvonen A, Drummond JE, DiNubile MJ, Heaton PM, Human Rotavirus Vaccine Study Group. 2006. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. *N Engl J Med* 354:23–33.
- Wakuda M, Nagashima S, Kobayashi N, Pongsuwanna Y, Taniguchi K. 2003. Serologic and genomic characterization of a G12 human rotavirus in Thailand. *J Clin Microbiol* 41:5764–5769.
- Wakuda M, Pongsuwanna Y, Taniguchi K. 2005. Complete nucleotide sequences of two RNA segments of human picobirnavirus. *J Virol Methods* 126:165–169.
- Zhou Y, Supawadee J, Khamwan C, Tonusin S, Peerakome S, Kim B, Kaneshi K, Ueda Y, Nakaya S, Akatani K, Maneekarn N, Ushijima H. 2001. Characterization of human serotype G9 isolated in Japan and Thailand from 1995 to 1997. *J Med Virol* 65:619–628.



Contents lists available at ScienceDirect

Virology

journal homepage: [www.elsevier.com/locate/yviro](http://www.elsevier.com/locate/yviro)

## The molecular chaperone heat shock protein-90 positively regulates rotavirus infection

Dipanjan Dutta<sup>a</sup>, Parikshit Bagchi<sup>a</sup>, Arunachal Chatterjee<sup>b</sup>, Mukti Kant Nayak<sup>a</sup>, Anupam Mukherjee<sup>a</sup>, Shiladitya Chattopadhyay<sup>a</sup>, Shigeo Nagashima<sup>c</sup>, Nobumichi Kobayashi<sup>c</sup>, Satoshi Komoto<sup>d</sup>, Koki Taniguchi<sup>d</sup>, Mamta Chawla-Sarkar<sup>a,\*</sup>

<sup>a</sup> Division of Virology, National Institute of Cholera and Enteric Diseases, P-33, C.I.T. Road, Scheme-XM, Beliaghata, Kolkata-700010, West Bengal, India

<sup>b</sup> Department of Zoology, University of Calcutta, Ballygunge Circular Road, Kolkata-700019, India

<sup>c</sup> Department of Hygiene, Sapporo Medical University, S-1 W-17, Chuo-ku, Sapporo 060-8556, Japan

<sup>d</sup> Department of Virology and Parasitology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

### ARTICLE INFO

#### Article history:

Received 20 May 2009

Returned to author for revision 7 June 2009

Accepted 26 June 2009

Available online xxx

#### Keywords:

Rotavirus

NF- $\kappa$ B

Akt

HSP90

17-AAG

Geldanamycin analogs

### ABSTRACT

Rotaviruses are the major cause of severe dehydrating gastroenteritis in children worldwide. In this study, we report a positive role of cellular chaperone Hsp90 during rotavirus infection. A highly specific Hsp90 inhibitor, 17-allylamono-demethoxygeldanamycin (17-AAG) was used to delineate the functional role of Hsp90. In MA104 cells treated with 17-AAG after viral adsorption, replication of simian (SA11) or human (KU) strains was attenuated as assessed by quantitating both plaque forming units and expression of viral genes. Phosphorylation of Akt and NF- $\kappa$ B observed 2–4 hpi with SA11, was strongly inhibited in the presence of 17-AAG. Direct Hsp90–Akt interaction in virus infected cells was also reduced in the presence of 17-AAG. Anti-rotaviral effects of 17-AAG were due to inhibition of activation of Akt that was confirmed since, PI3K/Akt inhibitors attenuated rotavirus growth significantly. Thus, Hsp90 regulates rotavirus by modulating cellular signaling proteins. The results highlight the importance of cellular proteins during rotavirus infection and the possibility of targeting cellular chaperones for developing new anti-rotaviral strategies.

© 2009 Elsevier Inc. All rights reserved.

### Introduction

Cells induce a stress response to virus infection, which results in the expression of stress response proteins like heat shock proteins (Hsps) (Sullivan and Pipas, 2001). It has been reported that both DNA and RNA viruses induce Hsps, independent of the cytoplasmic or nuclear location of their replication however the type of Hsp induced, depends on the virus or the cell type (Sedger and Ruby, 1994; Sullivan and Pipas, 2001). Hsp family members including Hsp40, 70 and 90 (40-, 70-, 90-kDa heat shock proteins) are also important molecular chaperones which regulate various cellular processes such as protein folding, transport, cell viability etc (Welch, 1991). While some viruses in the *Polyomaviridae* and *Closteroviridae* families encode their own viral specific chaperone proteins, most of the viruses have been shown to directly or indirectly depend on one or more cellular chaperones including, Hsp40 (Glotzer et al., 2000; Kumar and Mitra, 2005), Hsp70 (Mayer, 2005), Hsp90 (Hu and Seeger, 1996; Gilmore et al., 1998; Hung et al., 2002; Burch and Weller, 2005; Kampmueller and Miller, 2005; Okamoto et al., 2006; Connor et al., 2007; Naito et al., 2007;

Chase et al., 2008; Ujino et al., 2009) and cyclophilins (Franke et al., 1994) to complete their replication. There are overwhelming evidences suggesting the dependence of both DNA and RNA viruses on cellular chaperones however functional mechanism varies among different viruses and host systems (Hu and Seeger, 1996; Hung et al., 2002; Mayer, 2005; Connor et al., 2007).

Hsp90 is a constitutive, atypical member of the molecular chaperone family present in eukaryotes and bacteria. It is an extremely abundant protein, comprising ~1–2% of total cellular protein (Powers and Workman, 2006). Hsp90 displays ATP-dependent folding capacity and has been shown to bind during later stages of protein folding for facilitating the activation-competent state, with the help of its various co-chaperones and ATP (Nollen and Morimoto, 2002; Pearl and Prodromou, 2006; Powers and Workman, 2006). Unlike the other promiscuous cousin chaperone Hsp70, Hsp90 appears to have a specific set of client proteins (Nollen and Morimoto, 2002; Pearl and Prodromou, 2006). The common denominator of the Hsp90 client proteins, is their role as regulators of signal transduction pathways involved in cell cycle or survival, thus maintaining cellular homeostasis (Zhang and Burrows, 2004; Citri et al., 2006). The Hsp90 may contribute to viral replication either by modulating the cellular signaling mechanisms (Sun et al., 2008) or by direct interactions with viral proteins such as hepatitis B (HBV) reverse transcriptase, hepatitis

\* Corresponding author. Fax: +91 33 2370 5066.

E-mail addresses: [chawlam70@gmail.com](mailto:chawlam70@gmail.com), [sarkarmc@icmr.org.in](mailto:sarkarmc@icmr.org.in) (M. Chawla-Sarkar).

C NSP2/3 protein or RNA dependent RNA polymerase of Influenza A and vesicular stomatitis viruses (Hu and Seeger, 1996; Connor et al., 2007; Naito et al., 2007; Chase et al., 2008; Ujino et al., 2009).

Rotavirus is a double stranded RNA virus associated with severe dehydrating gastroenteritis in children worldwide. Children from underdeveloped countries, account for >80% of the rotavirus associated deaths (Rossen et al., 2004; Estes and Kapikian, 2007). The infectious virion is a non-enveloped, 11 dsRNA segmented genome surrounded by three concentric layers of protein. Rotavirus generally infects and replicates in mature enterocytes of the small intestine, leading to induction of inflammatory cytokines, reduced expression of enterocyte genes and vacuolization (Estes and Kapikian, 2007). Involvement of Hsc70 (70-kDa heat shock cognate protein) in the multistep entry of RV into intestinal epithelial cells and induction of heat shock protein transcripts following viral infection has been reported previously (Cuadras et al., 2002; Guerrero et al., 2002). However unlike the positive role of Hsps in facilitating replication in case of Influenza or HBV viruses, Hsp70 was found to negatively control RV infection by directing viral proteins towards ubiquitin dependent degradation. Silencing of Hsp70 resulted in increased translation of rotavirus proteins (Broquest et al., 2007). In spite of the induction of Hsps during rotavirus infection, there is no information till date about the role of cellular Hsp90 in regulating rotavirus growth and replication.

To elucidate the role of molecular chaperone Hsp90 in rotavirus replication, we utilized 17-allylamono-demethoxygeldanamycin (17-AAG; NSC 330507), a highly specific but less toxic analogue of the benzoquinone ansamycin antibiotic geldanamycin (Sausville et al., 2003). Geldanamycin and its analogs bind to the ATP-binding pocket on Hsp90 and interferes with its chaperone functions (Stebbins et al., 1997). A significant reduction (~1.5–1.8 log) in viral titers was observed in the presence of 17-AAG in a dose and time dependent manner. To our knowledge this is the first report showing involvement of Hsp90 as a modulator of rotavirus infection. In an attempt to address the possible molecular mechanism of 17-AAG mediated regulation of virus growth we have identified a positive role of Hsp90 client proteins, Akt and NF- $\kappa$ B during rotavirus infection. The results emphasize an important role of cellular proteins during infection of rotaviruses.

## Results

### *Inhibition of Hsp90 suppresses the rotavirus replication*

The cytotoxicity of 17-AAG was tested in mock-infected MA104 cells treated with increasing concentrations of the inhibitor for 12–48 h in serum free conditions by measuring cell viability using MTS reduction assay measuring metabolic activity of cells. There were 96.5–94.6%; 92.2–88.5% and 87.7–83.3% viable cells at 24–48 h post treatment in the presence of 2.5  $\mu$ M–5  $\mu$ M–10  $\mu$ M of 17-AAG respectively. More than 80% viable cells after 48 h of treatment with 5–10  $\mu$ M 17-AAG was also confirmed by neutral red dye uptake assay. After 24 and 48 h, 97% and 93.8% viable cells were observed in DMSO (<0.4%) treated control cells in serum free conditions (Fig. 1A). Cell extracts prepared after 48 h were also subjected to immunoblotting using Hsp90 antibody to assess the effects of 17-AAG on Hsp90 expression. A 2–3 fold decrease in Hsp90 expression was observed following treatment with 5–10  $\mu$ M of 17-AAG for 48 h (Fig. 1A).

To assess whether Hsp inhibitor 17-AAG, could modulate rotavirus growth, MA104 cells were infected with prototype strain SA11 (moi 1). After adsorption, cells were incubated at 37 °C in maintenance media containing either 17-AAG (2.5–10  $\mu$ M) or DMSO control. Cells were harvested at 20 hour post infection (hpi) and viral titers were determined using plaque assay. SA11, a fast growing strain has high infectivity rate (>90%) in MA104 cells and results in >80% loss of cell viability within 24 h. Compared to no drug controls, 17-AAG reduced viral titers in a dose dependent manner. At 5  $\mu$ M and 10  $\mu$ M dose, there was reduction in viral titer by 1.6–1.8 log and 2.1–2.2 log ( $p < 0.01$ )


respectively (Fig. 1B). The data suggested that for efficient rotavirus replication, functional Hsp90 chaperone complex is required. Subsequent experiments were carried out with the effective but less toxic dose (5  $\mu$ M) of 17-AAG. To understand whether 17-AAG affects early or late stages of viral life cycle, a time course study of viral growth was done. The MA104 cells were infected with SA11 (simian) and KU (human) strains (moi 1) and recovered in the absence or presence of 17-AAG. 17-AAG had a significant effect on slowing virus growth and showed noticeable delay in virus growth as early as 8 h in fast growing strain SA11 and 16 h in slow growing human strain KU compared to only virus infected DMSO controls. At the end point, there was 1.6–1.7 log and 1.2–1.4 log reduction in viral titers of SA11 and KU in the presence of 17-AAG (Fig. 1C). To assess whether Hsp90 function is required during early or late stages of infection, MA104 cells were infected with SA11 and 17-AAG was added to the media at 0 hpi, 2 hpi and 4 hpi. After 20 h of infection, cells were harvested and viral titers were estimated. As shown in Fig. 1D, 17-AAG significantly inhibited virus growth even when added 2 hpi (0.8–1.0 log), however the inhibitory effect was reduced when drug was added after 4 h of infection (<0.3 log) indicating the importance of Hsp90 chaperone activity during early stages of infection.

To elucidate the effect of Hsp90 inhibition on expression of viral genes, MA104 cells were infected with strain SA11 (moi 3) in the presence of either 17-AAG or only DMSO. Cells were harvested at 8 hpi and viral VP6 (viral protein 6; inner capsid) and NSP4 transcripts were quantitated in triplicates by real time PCR using gene specific primers and GAPDH as endogenous control. There was 2.2–2.4 fold ( $p < 0.05$ ) reduction in VP6 and NSP4 transcripts (Fig. 1E). The decrease in expression of viral genes was further validated by assessing decrease in levels of viral proteins in the presence of 17-AAG by immunoblotting. Cellular extracts prepared at 12 hpi in the presence of 17-AAG showed 2.72, 2.4 and 3.0 fold decrease in expression of VP6, NSP4 and NSP1 proteins respectively compared to only virus treated controls (Fig. 2A).

The specificity of 17-AAG for HSP90 facilitates the study of HSP90-dependent cellular pathways. However, to independently confirm the role of HSP90 in rotavirus replication in MA104 cells using a genetic approach that did not rely on pharmacological inhibitors; we used RNAi to selectively downregulate the expression of HSP90. MA104 cells were transiently transfected with Hsp90 specific or matched negative control siRNAs for two consecutive days. After 24 h of second transfection, a 2 fold reduction in hsp90 was observed compared to controls (Fig. 2B). siRNA transfected MA104 cells were infected with SA11 and rotavirus growth was measured by quantitating VP6 transcript by real time PCR and protein expression by immunoblotting. Compared to only virus controls, more than 2.0 fold decrease in viral transcripts and VP6 protein expression was observed in Hsp90 siRNA transfected cells (Figs. 2C, D) confirming the functional role of Hsp90 during rotavirus growth. A 9–10% decrease ( $p > 0.05$ ) observed in the matched negative control siRNA transfected cells could be due to non specific toxicity associated with transfection (Fig. 2D).

### *Inhibition of rotavirus replication by 17-AAG correlates to downregulation of virus induced Akt phosphorylation*

Based on previous reports regarding activation of PI3K/Akt in virus survival (Cooray, 2004; Halasz et al., 2008; Sun et al., 2008) and modulation of Akt by Hsp90 (Fujita et al., 2002; Zhang and Burrows, 2004), the effect of Hsp90 inhibitor on rotavirus-induced Akt infection was analyzed. Cell lysates prepared at 4–12 hpi from cells either mock-infected or infected with SA11 (moi 3), were subjected to western blotting using p-Akt (ser473) and p-GSK-3  $\beta$  (glycogen synthase kinase-3  $\beta$ ) antibodies. Following rotavirus infection, a 5–7 fold increase in Akt phosphorylation was observed at 4, 8 and 12 hpi compared to 2–3.2 fold increase in p-GSK-3  $\beta$ . There was no significant change in basal Akt or GSK-3  $\beta$  levels indicating that rotavirus modulates only the activation of endogenous Akt (Fig. 3A). However, when post infection, cells were recovered in the presence of 17-AAG,




**Fig. 1.** HSP90 inhibitor 17-AAG inhibits rotavirus multiplication. (A) Viability of MA104 cells cultured in serum free medium supplemented with different concentrations of 17-AAG (0–10  $\mu$ M) is shown as percent cell viability as determined by MTS reduction assay with Cell titer 96<sup>®</sup> Aqueous One Solution Cell Proliferation assay kit (Promega) following treatment for 12, 24 and 48 h. After 48 h, cells were lysed and Hsp90 expression was analyzed by immunoblot analysis (0–10  $\mu$ M). Decrease in Hsp90 expression (2–3 folds) was observed in the presence of 17-AAG. (B) Dose dependent inhibition in viral titers (SA11) by 17-AAG as measured by plaque assay after 20 h post infection. In the presence of 5  $\mu$ M–10  $\mu$ M 17-AAG, 1.6–2.2 log inhibition ( $p < 0.05$ ; \* $p < 0.01$ ) was observed. (C) Time kinetics of inhibition of rotavirus strains (SA11 and KU) growth in the presence (■) or absence (♦) of 17-AAG (5  $\mu$ M) as measured by plaque assay. At respective end points, a 1.3–1.7 log inhibition was observed for KU and SA11 strains respectively. (D) Role of Hsp90 in initial stages of rotavirus infection was confirmed by addition of 17-AAG at 0 hpi, 2 hpi and 4 hpi. Cells were lysed after 20 h of infection and viral titers were determined by plaque assay. There was an increase in rotaviral titers when 17-AAG was added 2 or 4 h post infection compared to 0 hpi. (E) 17-AAG (grey bar) inhibits expression of VP6 and NSP4 gene transcripts (8 hpi) in MA104 cells compared to only virus (black bars) infected cells, as measured by real time PCR. GAPDH was used as endogenous control. The data shown represent mean  $\pm$  SD of three experiments. The decrease in viral titers and gene expression in the presence of 17-AAG was statistically significant ( $p < 0.05$ ).

and significant downregulation of rotavirus-induced phosphorylation of Akt (2.3–2.6 fold) and its substrate GSK-3  $\beta$  (2.0–2.1 fold), was observed compared to the only virus infected cells (Fig. 3B). Whether the effect of 17-AAG on Akt phosphorylation was due to direct or indirect interactions between Hsp90 and Akt was assessed by immunoprecipitation of cell lysates prepared following rotavirus infection (8 h) in the presence or absence of 17-AAG using Hsp90 antibody. The blots were probed with Akt and Hsp90 antibodies. As shown in Fig. 3C, in cells infected with rotavirus, Akt co-immunopre-

cipitated with Hsp90 (Fig. 3C, lane 2), which was significantly inhibited in virus infected cells treated with 17-AAG (Fig. 3C, lane 3). At 8 hpi, there was no difference in Hsp90 expression in the presence or absence of 17-AAG.

To confirm whether downregulation of p-Akt by 17-AAG, could be one of the possible mechanism of its antiviral effects, cells were infected with strain SA11 (moi 1) in the presence of p-Akt inhibitor (tricitriline 2.5  $\mu$ M), PI3K inhibitor (LY294002, 10  $\mu$ M), 17-AAG or DMSO controls. Cells were harvested in a time dependent manner and viral titers were



**Fig. 2.** Effect of Hsp90 inhibition on rotavirus gene expression. (A) Western blot analysis of VP6, NSP4 and NSP1 expression in the presence or absence of 17-AAG (12 hpi). 17-AAG significantly reduced expression of VP6, NSP4 and NSP1 proteins compared to cells infected with virus in the presence of DMSO. The blots were reprobbed with  $\beta$ -actin to confirm equal protein loading. Fold change was quantitated by measuring band intensities in respect to  $\beta$ -actin control ( $n = 3$ ;  $p < 0.05$ ;  $*p \leq 0.01$ ). (B) Downregulation of HSP90 expression in the presence of HSP90 siRNA (5 nM) as analyzed by western blotting. (C and D) Cells that were mock-transfected or transfected with HSP90 siRNA or matched negative control siRNA were infected with SA11 (moi 3). After 8 hpi or 12 hpi, cells were lysed and viral gene VP6 transcript or protein expression was measured by RTq PCR (C) and immunoblotting (D) showing significant reduction in expression of both VP6 transcripts as well as protein expression as a result of HSP90 silencing.

determined. In the presence of triciribine or LY294002, a 1.1–1.3 log reduction in viral titers was observed at 20 h compared to 1.6–1.7 log inhibition with 17-AAG, confirming the importance of virus induced activation of PI3K/Akt during its replication (Fig. 3D). The reduction in viral titers was not due to cytotoxic effects since in serum free conditions mimicking virus infection, there were 92.6–88.8% and 90.1–85.2% cell viability after 24–48 h of triciribine (2.5  $\mu$ M) and LY294002 (10  $\mu$ M) treatment (Fig. 3E). The virus induced phosphorylation of Akt was also inhibited, in the presence of both triciribine and LY294002 confirming correlation between inhibition of viral replication and Akt phosphorylation (data not shown). Positive role of Akt was further confirmed using Akt-1 and Akt-2 specific siRNAs. After 24 h of transfection, 60% decrease in Akt expression was observed compared to controls. Following SA11 infection in siRNA transfected MA104 cells, expression of VP6 protein was quantitated by immunoblotting. Compared to only virus controls, more than 3 fold decrease in VP6 protein expression was observed in Akt siRNA transfected cells (Fig. 3F).

#### 17-AAG inhibits Akt regulated mTOR signaling

Based on previous data confirming positive role of Akt, we hypothesized that 17-AAG may effect virus growth by inhibiting the Akt substrates such as regulator of the initiation of cap-dependent translation mTOR (mammalian target of rapamycin). Phosphorylation of mTOR, 4EBP1 (eukaryotic initiation factor 4E binding protein 1) and p70S6K (ribosomal p70 S6 kinase) was analyzed 12 h post infection (SA11) in the presence or absence of 17-AAG by immunoblotting. Rapamycin (100 nM), inhibitor of mTOR, was used as positive control. Rotavirus infection resulted in an increase in phosphorylation of


mTOR (> 10 fold), 4EBP1 ( $\geq 7$  fold) and p70S6K ( $\geq 5$  fold), which was significantly reduced in the presence of 17-AAG (Fig. 4). No change in expression of basal mTOR, 4EBP1 or S6K protein in the presence of 17-AAG was observed (Fig. 4).

#### 17-AAG inhibits activation of rotavirus-induced NF $\kappa$ B, another Hsp90 and Akt modulated protein

Since there are reports of activation of NF $\kappa$ B during rotavirus infection and NF $\kappa$ B is also activated by PI3K/Akt and Hsp90, we analyzed whether rotavirus-induced NF $\kappa$ B activation is modulated by 17-AAG. MA104 cells were infected with SA11 (moi 3) followed by the treatment with either 17-AAG or DMSO, and cell extracts were prepared at 2–8 h post infection. Immunoblotting with phospho-p65 antibody showed increased phosphorylation of p65 subunit of NF $\kappa$ B following rotavirus infection, as early as 2–4 h (2.5–3.5 fold) with subsequent decrease at 8 h (Fig. 5A) confirming previous observations. However there was a significant downregulation of p-p65 at 2 h (1.7 fold) and >4.5 fold inhibition by 4 h in the presence of 17-AAG (Fig. 5A). Inhibition of NF $\kappa$ B activation was further confirmed using a luciferase reporter construct with a 2 $\times$  NF $\kappa$ B promoter. A strong activation of NF $\kappa$ B promoter as measured by luciferase enzyme activity was observed 4 h and 8 hpi following rotavirus infection, which was inhibited 3–5 fold ( $p < 0.01$ ) in the presence of 17-AAG (Fig. 5B).

#### Discussion


All viruses depend on host cells for a successful infection, thus they need to create a cellular environment which is conducive for their



**Fig. 3.** Effect of 17-AAG on rotavirus-induced Akt phosphorylation. (A) Western blot analysis showing phosphorylation of Akt (ser473) and its downstream substrate GSK-3 β at 4–12 h post SA11 infection. Blots were probed to analyze basal expression of Akt or GSK-3 β following rotavirus infection. (B) 17-AAG (5 μM) inhibits the rotavirus (8 hpi) induced Akt and GSK-3 β phosphorylation. No effect of 17-AAG on basal Akt or GSK-3 β expression was observed. (C) Co-immunoprecipitation of Hsp90 with Akt is significantly reduced in the presence of 17-AAG. Cells were either mock-infected or infected with SA11 (moi: 3) in the presence or absence of 17-AAG. Cell lysates prepared at 8 hpi were immunoprecipitated with anti-Hsp90 antibody and separated on a 10% polyacrylamide gel. Blots were probed with Akt and Hsp90 antibody. Whole cell lysates were also loaded as internal control for Akt and Hsp90 protein. (D) Time kinetics of inhibition of SA11 growth in the presence of inhibitors namely, 17-AAG (5 μM ●), triciribine (2.5 μM ■), LY294002 (10 μM ▲) or DMSO control (♦) for 20 h as measured by plaque assay. The data represent the mean ± SD of three experiments ( $p < 0.05$ ). (E) Percent cell viability of MA104 cells incubated with triciribine (2.5 μM), LY294002 (10 μM) or DMSO as determined by MTS reduction assay with Cell titer 96® Aqueous One Solution Cell Proliferation assay kit (Promega) following 12, 24 and 48 h of treatment in serum free conditions. Individual data points represent the mean values from three independent experiments. (F) Downregulation of Akt expression by Akt siRNA (5 nM, Ambion) after 24 h of transfection in MA104 cells as confirmed by western blot analysis. Following Akt or negative control siRNA transfection, MA104 cells were infected with SA11 and expression of VP6 protein was quantitated after 12 h by immunoblotting. Significant reduction (3 fold) was observed in the expression of VP6 protein expression in the presence of Akt siRNA ( $p < 0.05$ ).

replication. To survive and evade host immune responses, viruses have developed the ability to exploit cellular signaling pathways regulating, the cell survival, homeostasis or apoptosis for their benefit. Thus identification of important cellular factors modulating viral growth is important to not only understand virus–host interactions but pathogenesis of the disease. Moreover the possibility of targeting cellular proteins for developing new generation of low cost antivirals specially in the case of short term viral infections is gaining importance due to its implications in reducing morbidity and mortality in developing countries (Lewis et al., 2000; Geller et al., 2007).

During the last decade, there are lots of reports regarding rotavirus diversity and epidemiology, vaccine development, gene expression, evasion of immune response by modulating IFN regulatory factors etc (Estes and Kapikian, 2007). In a microarray study following RV infection in CaCo2 cells, induction of heat shock protein transcripts was observed (Cuadras et al., 2002), but significance of the Hsp induction has not been studied. There are ample direct or indirect evidences supporting the positive role of heat shock proteins in modulating replication of many viruses (Connor et al., 2007; Geller et al., 2007; Sun et al., 2008; Chase et al., 2008; Ujino et al., 2009). Thus we hypothesized that induction of Hsp90 during rotavirus infection




**Fig. 4.** 17-AAG inhibits rotavirus-induced mTOR-4EBP1-p70S6K activation by Akt regulation. Western blot showing rotavirus (SA11) induced phosphorylation of mTOR, 4EBP1 and p70S6K at 12 hpi. In the presence of 17-AAG, phosphorylation of mTOR-4EBP1-p70S6K was inhibited 3.7, 2.0 and 2.5 fold respectively compared to only virus treated cells. There was no change in expression of basal mTOR, 4EBP1 or p70S6K proteins following treatment with 17-AAG. Rapamycin was used as positive control. The blots were reprobred with β-actin to confirm equal protein loading.

may also have a role in either negative or positive regulation of viral replication. In this report, we establish that rotavirus growth is positively dependent on Hsp90 and its downstream client proteins.

17-AAG, a cell permeable analogue of geldanamycin binds to the ATP-binding pocket within the N-terminal domain of Hsp90 disrupting its chaperone activity (Sausville et al., 2003). Depletion of Hsp90β and modulation of various signaling proteins following treatment with 17-AAG in HT29 has been shown previously by gene expression profiling and proteomic analysis. Downregulation of Hsp90β following 17-AAG treatment for longer periods is probably due to proteosomal degradation of inactive Hsp90 (Clarke et al., 2000). In the presence of 17-AAG, reduction in viral titers was observed irrespective of species or serotype specificity of rotaviral strains. Similar inhibition of rotavirus growth by 17-AAG was also observed in HT29 (24 h) and CaCo2 (40 h) cells (data not shown). At dose or time used in the study (5 µM/24 h), 17-AAG showed minimal cytotoxicity as determined by MTS assay or neutral red uptake, indicating that inhibition of viral growth was not due to cytotoxicity. Moreover the downregulation of Hsp90 expression by RNA interference also resulted in decrease in rotavirus replication. The reduction in viral gene transcripts or protein in the presence of 17-AAG was also not due to global downregulation of cellular gene expression since under similar conditions (8–12 hpi) expression of cellular genes namely β-actin, GAPDH, Akt, mTOR, p70S6K etc was not altered. Based on the studies where inhibitor was added at different time points after virus infection, it can be deduced that in conditions used during the study the anti-rotavirus effects of 17-AAG were during initial stages of infection since the inhibitory effects of 17-AAG were significantly reduced when a drug was added after 4 h of adsorption compared to 0 hour post adsorption. The reduced viral growth observed during the study is not due to inhibition in virus entry since in all experiments, the inhibitor was added after virus adsorption (45 min). Trypsin activated rotaviruses have been shown to internalize in MA104 cells within 3–5 min of the adsorption (Kaljot et al., 1988).

Based on our observations and lack of any previous reports, we first tried to elucidate the role of Hsp90 in modulating rotavirus-induced intracellular signaling pathways. Hsp90 has been shown to interact with more than 100 protein kinases and associated proteins regulating their biogenesis, stability and activity (Zhang and Burrows, 2004; Citri et al., 2006). Hsp inhibitors have been reported to affect activities of Akt, IκappaB kinase, receptor interacting protein (RIP), NFκB inducing kinase (NIK), Death associated protein kinases (DAPK), cyclin dependent kinases, p53 etc (Lewis et al., 2000; Fujita et al., 2002; Broemer et al., 2004; Zhang and Burrows, 2004; Citri et al., 2006). Activation of the cell survival signals like PI3K/Akt and NFκB has been implicated in maintaining short term cell viability for facilitating pathogen replication during infections. After the production of viral progeny, virus particles are released by downregulation of prosurvival pathways and induction of apoptosis (Cooray, 2004; Sun et al., 2008; Ehrhardt and Ludwig, 2009).

PI3K/Akt activation during rotavirus infection has been shown to modulate integrin expression and positively regulate rotavirus replication (Halasz et al., 2008). In this study too we observed



**Fig. 5.** 17-AAG inhibits rotavirus-induced activation of Hsp90 client protein NFκB. (A) Immunoblotting with phospho-NFκB p65 antibody revealed a significant increase in phosphorylation of p65 subunit (2–4 h), which was inhibited 1.75–4.5 fold ( $p < 0.05$ ;  $n = 3$ ) in the presence of 17-AAG. There was no change in the expression of p65 in the presence or absence of 17-AAG following 8 h of treatment. (B) NFκB promoter activity was measured in the presence or absence of 17-AAG (4 hpi and 8 hpi) using a 2× NFκB-luc plasmid. Significant inhibition in activation of NFκB promoter was observed at 4 hpi ( $p < 0.05$ ;  $n = 4$ ) and 8 hpi ( $*p < 0.01$ ) compared to only virus infected cells. Mean relative luciferase activity of NFκB-luciferase was normalized with Renilla luciferase.

phosphorylation of Akt and its downstream substrate GSK-3 $\beta$ , up to 12 h, following rotavirus infection which was inhibited (>2.2 fold) in the presence of 17-AAG. Unlike previous report (Halasz et al., 2008), where Akt activation was observed from 1 h to 8 h depending on cell type with RRV and CRW8 strains, we observed p-Akt until 12 hpi with SA11 strain in MA104 cells, whereas following infection with KU strain, p-Akt was observed only at 2–6 hpi (unpublished observation) indicating strain specific differences. Importance of Akt activation during rotavirus infection was re-confirmed when triciribine, a specific inhibitor of phospho-Akt-1 and Akt-2 (Yang et al., 2004) as well as general PI3K inhibitor LY294002 reduced rotaviral titers in a time dependent manner. The inhibitory effect on viral growth was not due to non specific effects of chemical inhibitors since Akt specific siRNAs, but not control siRNA inhibited the viral gene expression. Based on a previous study by Halasz et al. (2008), and our observations, it is clear that activation of PI3K/Akt positively regulates rotavirus replication. Hsp90 chaperone cycle has been shown to activate associated client protein Akt/PKB by phosphorylation (Citri et al., 2006). Thus 17-AAG mediated inhibition of Hsp90 may be one of the possible mechanisms of inhibition of Akt signaling.

Earlier *in-vivo* study has shown activated p70S6k in crypt cells of rotavirus infected piglets (Rhoads et al., 2007). PI3K/Akt signaling has also been implicated in translational control. Regulation of Tor kinase regulates translation through two independent pathways, involving p70S6 kinase (S6K) and the initiation factor 4E (eIF-4E)-binding protein-1 (4E-BP1). S6K phosphorylation enhances translation of 5' TOP mRNA, containing oligopyrimidine tract which encodes for ribosomal proteins and elongation factors (Jefferies et al., 1997). Phosphorylation of 4E-BP1, a negative regulator of translation initiation, inhibits its interaction with eIF-4E, which binds to m7GpppN cap of mRNA and directs its correct positioning of ribosomal units to relieve translational block (Gingras et al., 2001). In the presence of 17-AAG, virus induced phosphorylation of mTOR-4EBP1-p70S6K was significantly decreased, which could be partly responsible for inhibition of cap-dependent translation of rotaviral RNAs, further confirming the importance of Akt signaling for virus multiplication.

Other than Akt, Hsp90 inhibition may affect one or more other client proteins associated with modulation of cellular homeostasis. We looked at the effect on NF $\kappa$ B, since previous reports suggested activation of NF $\kappa$ B by rotavirus capsid protein VP4 through interaction with TRAF2 (La Monica et al., 2001), and induction of IL8 in rotavirus infected intestinal epithelial cells (Casola et al., 1998; Rollo et al., 1999). In addition Akt is also implicated in activation of NF $\kappa$ B via I $\kappa$ B kinase pathway (Ozes et al., 1999) and disruption of Hsp90 function has been shown to inhibit NF $\kappa$ B activation by modulating RIP (Lewis et al., 2000). However recent reports have shown rotavirus mediated inhibition of NF $\kappa$ B translocation to nucleus as a mechanism of antagonizing cellular antiviral responses (Holloway et al., 2009) and possible role of NSP1 in the process (Graff et al., 2009). In contrast NF $\kappa$ B specific inhibitors have been shown to inhibit rotavirus replication (Rossen et al., 2004). In these studies too authors have observed activation of NF $\kappa$ B following RRV, Wa or NCDV infection during initial stages but have concluded that during later stages when rotavirus replication is established and rotavirus proteins are expressed, nuclear translocation of p65 NF $\kappa$ B is inhibited to restrict induction of NF $\kappa$ B driven antiviral cytokines like IFN $\beta$  or IL8 (Holloway et al., 2009; Graff et al., 2009). A time course study comparing various rotavirus strains from human and animal origin in different cell lines may solve the fine balance of both proviral and antiviral functions of NF $\kappa$ B during rotavirus infection. In this study too, SA11 infection (2–8 hpi), induced both phosphorylation of p65 and NF $\kappa$ B promoter activation confirming previous observations. Increase in IL8 transcript (>50 fold) in MA104 cells following SA11 infection (4–8 hpi), was also observed by real time PCR (data not shown). The activation of virus induced NF $\kappa$ B was significantly reduced in the

presence of 17-AAG indicating that NF $\kappa$ B inhibition also partly contributes to antiviral effects of 17-AAG. Hsp90 may also have additional direct effects or may modulate other unknown client proteins during rotavirus infection which requires further studies.

Viral inhibition through regulation of cellular machinery could be exploited further as an antiviral approach with double benefits of avoiding the development of resistant viral strains as well as having a broad spectrum antiviral activity. In case of emergence of new variants of virus causing outbreaks, this would prove to be useful in controlling the infection, before viral target proteins are characterized or vaccines are developed. This report highlights the role of chaperone protein Hsp90 in positive regulation of rotavirus growth possibly by modulating virus induced activation of cellular signaling pathways. Targeting molecular chaperones like Hsp90 for developing antiviral drugs has additional benefits, i) a broad range of DNA and RNA viruses have been reported to be inhibited by geldanamycin analogs and ii) chaperones being evolutionarily conserved proteins, the probability of generation of drug resistant variants is expected to be extremely low (Geller et al., 2007). The high morbidity and mortality associated with rotavirus-induced diarrhea, emphasize the need for evaluating low toxicity inhibitors targeting cellular proteins as future anti-rotaviral strategies.

## Materials and methods

### Chemicals

Inhibitors for Hsp90 (17-AAG), PI3Kinase (LY294002), phospho-Akt (triciribine), mTOR (rapamycin) were purchased from Invivogen (San Diego, CA) and Biomol (Plymouth Meeting, PA). Other fine chemicals and buffers used in the study were from Sigma-Aldrich (St. Louis, MO).

### Cell culture and virus infection

The monkey kidney cell line (MA104) was cultured in minimal essential medium (MEM), supplemented with US certified 10% fetal bovine serum and 1% antibiotic-antimycotic solution (Invitrogen, Carlsbad, CA). Cells were maintained in 5% CO<sub>2</sub> at 37 °C humidified incubator. The simian rotavirus SA11 [H96] and human rotavirus Ku strains were used in the study. For infection, viruses were activated with acetylated trypsin (10  $\mu$ g/ml) at 37 °C for 30 min, diluted as per required multiplicity of infection (moi) and added to the cells for adsorption (45 min) at 37 °C, followed by washing 3 $\times$  with media to remove unbound virus. Infection was continued in fresh medium. Except for viral growth assays (moi 1), moi 3 was used in the study. The time of virus removal was taken as 0 hour post infection (hpi) for all experiments. At different time points cells were freeze-thawed for cell lysis. Extracted and purified viral preparations by glycerol gradient (30–60%v/v) ultracentrifugation were titrated by plaque assay (Jolly et al., 2000). The end point in experiments were determined based on time required by virus to complete its replication in cells resulting in >80% CPE as determined by neutral dye uptake assay. The end point for SA11 and KU strain varied from 20 to 40 h depending on replication cycle of viruses. In all experiments DMSO ( $\leq$ 0.25%) was added in mock-infected controls to rule out any adverse effects of DMSO. The different inhibitors used in the study were added after adsorption of virus and addition of maintenance media (0 hpi).

### Plaque assay

Monolayers of MA104 cells in six well plates were infected with serial dilutions (10<sup>2</sup>–10<sup>8</sup>) of viral supernatants as described earlier. After 45 min of adsorption, inoculum was removed and cells were overlaid with 0.7% agar in 1 $\times$ MEM with 1  $\mu$ g/ml trypsin. After 36–48 h post infection second agar overlay (0.7% agar in 1 $\times$ MEM with 0.1%

neutral red) was added and plates were incubated at 37 °C until plaques were visualized. Viral plaque forming units were calculated as described previously (Smith et al., 1979). >1 log inhibition in viral titers is equivalent to >90% inhibition.

#### Cell viability assay (MTS assay)

Cell viability in the presence or absence of different inhibitors (17-AAG, LY294002, trichiribine) was determined by Cell titer 96<sup>®</sup> Aqueous One Solution Cell Proliferation assay kit (Promega, Madison, WI, USA) which contains [3-(4, 5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, inner salt]; MTS) and an electron coupling reagent (phenazine ethosulphate; PES). MTS gets bioreduced to form soluble coloured formazan by NADPH or NADH produced by dehydrogenase enzymes in metabolically active cells. Briefly, cells with ~80% confluency in 96 well plates were incubated with different inhibitors or DMSO for indicated time periods. At the end of each incubation period cells were treated with 20 µl of the reagent solution in 100 µl serum free medium for 4 h at 37 °C in a humidified 5% CO<sub>2</sub> atmosphere. The quantity of the soluble formazan product was measured spectrophotometrically at 490 nm in Varioskan Multimode Reader, Thermofisher. The absorbance was directly proportional to the number of living cells in culture. The percent viability was calculated considering 100% viability for untreated control cells at similar end points.

#### Neutral dye uptake

Cellular activity in the presence of different inhibitors was determined using uptake of vital stain Neutral Red (NR). The process requires intact membranes and active metabolism in the cells. Based on the principle that living and healthy cells take up more dye, MA104 or HT29 cells were plated on 12 well dishes to 70–80% confluency. Next day, cells were treated with different concentrations of the inhibitors (17-AAG, trichiribine or LY294002). The assay was also utilized to determine the end point after virus infection (80% CPE). After the requisite time intervals, plates were washed with PBS 3× and fresh 500 µl media containing neutral red dye (50 µg/ml) was added. After 3 h of incubation, excess dye was washed with PBS 2× and 500 µl of desorbing solution (1% acetic acid, 50% ethanol) was added to extract the absorbed dye. Absorbance was taken at 405 nm and 540 nm in a microplate reader. The % cell viability was calculated considering 100% viability of untreated controls.

#### Gel electrophoresis and immunoblot analyses

Whole cell lysates were prepared and immunoblotting was done as per standard protocols (Chawla-Sarkar et al., 2002). Rabbit polyclonal antibodies (pAb) to Akt, GSK-3 β, NFκB(P65), 4EBP1, S6K, p-Akt, p-GSK-3 β, p-NFκB(P65), p-mTOR, p-4EBP1(Thr37/46), p-p70S6K (Cell Signaling Inc, Devers, MA), or mouse monoclonal antibodies (mAb) to Hsp90, Hsp70 (BD Pharmingen, San Diego, CA) were used at concentrations recommended by the manufacturer. Rotavirus non structural protein-1 and -4 (NSP1; NSP4) antibodies (polyclonal) were raised in rabbit using standard protocols. Monoclonal mouse VP6 antibody (3C10) was purchased from HyTest Ltd, Turku, Finland. Primary antibodies were detected using HRP-conjugated secondary antibodies (Pierce, Rockford, IL) and chemiluminescent substrate (Millipore, Billerica, MA). Blots were reprobbed with anti-β-actin or unphosphorylated proteins to confirm equal protein loading. All immunoblots in this study were repeated ( $n \geq 3$ ) to confirm results. Blots were scanned and quantitated using GelDoc XR system and Quantity One<sup>®</sup> software version 4.6.3 (BioRad, Hercules, CA).

#### Dual luciferase NFκB reporter assay

The NFκB-luciferase (NFκB-luc) reporter plasmid has been previously characterized (Elewaut et al., 1999). MA104 cells were co-transfected with 4 µg of NFκB-luc and 0.5 µg of pRL-TK (Promega, Madison, WI) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). After 24 h, cells were infected with SA11 for 4 h and 12 h in the presence or absence of 17-AAG, and luciferase activity was measured according to the manufacturer's protocol (Promega, Madison, WI) using a luminometer (Varioskan Multimode Reader, Thermofisher). Relative luciferase activity of NFκB-luciferase was normalized with *Renilla* luciferase.

#### Quantitative real-time RT-PCR

Confluent monolayers of MA104 cells were mock-infected or infected with SA11 (moi 3). RNA was extracted with TRIZOL<sup>™</sup> reagent (Invitrogen, USA) and quantitative PCR was done in triplicates using SYBR Green<sup>™</sup> Mastermix using ABI7500 (Applied Biosystems Inc, Foster city, CA). Specific primers for VP6 [VP6-F-5'GCACAGCCATTC-GAACATCATGC-3'; VP6-R-5'TGCATCGGCGAGTACAGAC TAC-3'], Nsp4 [Nsp4-F-5'GACGGTCAAACGAC AGCGC-3'; Nsp4-R-5'GCTGCAGT-CACCTTCTTGGTTC-3']; and GAPDH [G-F-5'GAGA ACGGGAAGCTTGT-CATC-3'; G-R-5'CATGACGAACATGGGGGCATC-3'], were used. Relative gene expression were normalized to GAPDH using the formula  $2^{-\Delta\Delta CT}$  [ $\Delta\Delta CT = \Delta CT$  (sample) –  $\Delta CT$  (untreated control)].

#### RNA interference using siRNAs

Monolayers of MA104 cells ( $10^6$  cells/ml) in 6 well plates were transfected with either *Silencer<sup>®</sup> Select Hsp90* (5nM X2;48h) cytosolic [Ambion ID: s6995], or *Silencer<sup>®</sup> Select Akt* siRNA (5 nM each; 24 h) [Ambion (ID: S659 and ID: S1216)] or 5 nM *Silencer<sup>®</sup> Select Negative Control #2* siRNA (Ambion, Foster city, CA) using siPORT<sup>™</sup> NeoFX transfection reagent (Ambion) according to the manufacturer's protocol. 24 h post transfection cells were infected with SA11 (moi: 3) for 8 h or 12 h, lysed and VP6 gene expression was measured by either quantitative PCR or immunoblotting.

#### Statistical analysis

Data are expressed as mean ± standard deviations of at least three independent experiments ( $n \geq 3$ ). In all tests,  $p < 0.05$  was considered statistically significant. Experiments where,  $p < 0.01$  are marked (\*).

#### Acknowledgments

The study was supported by financial assistance from the Indian Council of Medical Research (ICMR), New Delhi and the Program of founding research centers for emerging and reemerging infectious diseases (Okayama University-NICED, India) from the Ministry of Education, Culture, Sports, Science and Technology, Japan. D. Dutta, A. Mukherjee and M.K. Nayak are supported by the Senior Research Fellowship from UGC, Govt. of India.

#### References

- Broemer, M., Krappmann, D., Scheidereit, C., 2004. Requirement of Hsp90 activity for IκappaB kinase (IKK) biosynthesis and for constitutive and inducible IKK and NF-kappaB activation. *Oncogene* 23 (31), 5378–5386.
- Broquest, A.H., Lenior, C., Gardet, A., Sapin, C., Chwetzoff, S., Jouniaux, A.M., Lopez, S., Trugnan, G., Bachelet, M., Thomas, G., 2007. HSP70 negatively controls rotavirus protein bioavailability in Caco-2 cells infected by rotavirus RF strain. *J. Virol.* 81 (3), 1297–1304.
- Burch, A.D., Weller, S.K., 2005. Herpes simplex virus type 1 DNA polymerase requires the mammalian chaperone hsp90 for proper localization to the nucleus. *J. Virol.* 79 (16), 10740–10749.

- Casola, A., Estes, M.K., Crawford, S.E., Ogra, P.L., Ernst, P.B., Garofolo, R.P., Crowe, S.E., 1998. Rotavirus infection of cultured intestinal epithelial cells induces secretion of CXCL10 and CXCL12 chemokines. *Gastroenterology* 114 (5), 947–955.
- Chase, G., Deng, T., Fodor, E., Leung, B.W., Mayer, D., Schwemmler, M., Brownlee, G., 2008. Hsp90 inhibitors reduce influenza virus replication in cell culture. *Virology* 377 (2), 431–439.
- Chawla-Sarkar, M., Leaman, D.W., Jacobs, B.S., Borden, E.C., 2002. IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis. *J. Immunol.* 169 (2), 847–855.
- Citri, A., Harari, D., Shohat, G., Ramakrishnan, P., Gan, J., Lavi, S., Eisenstein, M., Kimchi, A., Wallach, D., Pietrokovski, S., Yarden, Y., 2006. Hsp90 recognizes a common surface on client kinases. *J. Biol. Chem.* 281 (20), 14361–14369.
- Clarke, P.A., Hostein, L., Banerji, U., Stefano, F.D., Maloney, A., Walton, M., Judson, L., Workman, P., 2000. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. *Oncogene* 19 (36), 4125–4133.
- Connor, J.H., McKenzie, M.O., Parks, G.D., Lyles, D.S., 2007. Antiviral activity and RNA polymerase degradation following HSP90 inhibition in a range of negative strand virus. *Virology* 362 (1), 109–119.
- Cooray, S., 2004. The pivotal role of phosphatidylinositol 3-kinase-Akt signal transduction in virus survival. *J. Gen. Virol.* 85 (pt 5), 1065–1076.
- Cuadras, M.A., Feigelstock, D.A., An, S., Greenberg, H.B., 2002. Gene expression pattern in Caco-2 cells following rotavirus infection. *J. Virol.* 76 (9), 4467–4482.
- Ehrhardt, C., Ludwig, S., 2009. A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway. *Cell. Microbiol.* 11 (6), 863–871.
- Elewaut, D., DiDonato, J.A., Kim, J.M., Truong, F., Eckmann, L., Kagnoff, M.F., 1999. NF-kappa B is a central regulator of the intestinal epithelial cell innate immune response induced by infection with enteroinvasive bacteria. *J. Immunol.* 163 (3), 1457–1466.
- Estes, M.K., Kapikian, A.Z., 2007. Rotavirus. In: Knipe, D.M., Howley, P.N., Griffin, D.E., Lamb, R.A., Martin, M.A., Roizman, B., Straus, E.E. (Eds.), *Fields Virology*, 5th ed. Lippincott Williams and Wilkins, Philadelphia, pp. 1917–1974.
- Franke, E.K., Yuan, H.E., Luban, J., 1994. Specific incorporation of cyclophilin A into HIV-1 virions. *Nature* 372 (6504), 359–362.
- Fujita, N., Sato, S., Ishida, A., Tsuruo, T., 2002. Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. *J. Biol. Chem.* 277 (12), 10346–10353.
- Geller, R., Vignuzzi, M., Andine, R., Fryman, J., 2007. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. *Genes Dev.* 21 (2), 195–205.
- Gilmore, R., Coffey, M.C., Lee, P.W., 1998. Active participation of HSP90 in the biogenesis of the trimeric reovirus cell attachment protein sigma1. *J. Biol. Chem.* 273 (24), 15227–15233.
- Gingras, A.C., Raught, B., Sorenberg, N., 2001. Regulation of translation initiation by FRAP/mTOR. *Genes Dev.* 15 (7), 807–826.
- Glotzer, J.B., Saltik, M., Chiozza, S., Moseley, P., Cotton, M., 2000. Activation of heat-shock response by an adenovirus is essential for virus replication. *Nature* 407 (6801), 207–211.
- Graff, J.W., Ettayebi, K., Hardy, M.E., 2009. Rotavirus NSP1 inhibits NFkB activation by inducing proteasome-dependent degradation of  $\beta$ -TrCP: a novel mechanism of IFN antagonism. *PLoS Pathog.* 5 (1), e1000280.
- Guerrero, I.A., Bouyssonnade, D., Zarate, S., Ista, P., Lopez, T., Espinosa, R., Romero, P., Méndez, E., López, S., Arias, C.F., 2002. Heat shock cognate protein 70 is involved in rotavirus cell entry. *J. Virol.* 76 (8), 4096–4102.
- Halasz, P., Holloway, G., Turner, S.J., Coulson, B.S., 2008. Rotavirus replication in intestinal cells differentially regulates integrin expression by a phosphatidylinositol 3-kinase-dependent pathway, resulting in increased cell adhesion and virus yield. *J. Virol.* 82 (1), 148–160.
- Holloway, G., Truong, T.T., Coulson, B.S., 2009. Rotavirus antagonizes cellular antiviral responses by inhibiting the nuclear accumulation of STAT1, STAT2, and NF- $\kappa$ B. *J. Virol.* 83 (10), 4042–4951.
- Hu, J., Seeger, C., 1996. Hsp90 is required for the activity of hepatitis B virus reverse transcriptase. *Proc. Natl. Acad. Sci. U.S.A.* 93 (3), 1060–1064.
- Hung, J.J., Chung, C.S., Chang, W., 2002. Molecular chaperone HSP90 is important for vaccinia virus growth in cells. *J. Virol.* 76 (3), 1379–1390.
- Jefferies, H.B., Fumagalli, S., Dennis, P.B., Reinhard, C., Pearson, R.B., Thomas, G., 1997. Rapamycin suppresses 5' TOP mRNA translation through inhibition of p70s6k. *EMBO J.* 16 (12), 3693–3704.
- Jolly, C.L., Beisner, B.M., Holmes, L.H., 2000. Rotavirus infection of MA104 cells is inhibited by Ricinus lectin and separately expressed single binding domains. *Virology* 275 (1), 89–97.
- Kaljot, K.T., Shaw, R.D., Rubin, D.H., Greenberg, H.B., 1988. Infectious rotavirus enters cells by direct cell membrane penetration, not by endocytosis. *J. Virol.* 62 (4), 1136–1144.
- Kampmueller, K.M., Miller, D.J., 2005. The cellular chaperone heat shock protein 90 facilitates flock house virus RNA replication in *Drosophila* cells. *J. Virol.* 79 (11), 6827–6837.
- Kumar, M., Mitra, D., 2005. Heat shock protein 40 is necessary for human immunodeficiency virus-1 Nef-mediated enhancement of viral gene expression and replication. *J. Biol. Chem.* 280 (48), 40041–40050.
- La Monica, R., Kocer, S.S., Nazarova, J., Dowling, W., Geimonen, E., Shaw, R., Mackow, E.R., 2001. VP4 differentially regulates TRAF2 signaling, disengaging JNK activation while directing NF- $\kappa$ B to effect rotavirus specific cellular responses. *J. Biol. Chem.* 276 (23), 19889–19896.
- Lewis, J., Devin, A., Miller, A., Lin, Y., Rodriguez, Y., Neckers, L., Liu, Z.G., 2000. Disruption of hsp90 function results in degradation of the domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation. *J. Biol. Chem.* 275 (14), 10519–10526.
- Mayer, M.P., 2005. Recruitment of Hsp70 chaperones: a crucial part of viral survival strategies. *Rev. Physiol. Biochem. Pharmacol.* 153, 1–46.
- Naito, T., Tomose, F., Kawaguchi, A., Nagata, K., 2007. Involvement of HSP90 in assembly and nuclear import of influenza virus RNA polymerase subunits. *J. Virol.* 81 (3), 1339–1349.
- Nollen, E.A., Morimoto, R.L., 2002. Chaperoning signaling pathways: molecular chaperones as stress-sensing 'heat shock' proteins. *J. Cell Sci.* 115 (pt 14), 2809–2816.
- Okamoto, T., Nishimura, Y., Ichimura, T., Suzuki, K., Miyamura, T., Suzuki, T., Moriishi, K., Matsuura, Y., 2006. Hepatitis C virus RNA replication is regulated by FKBP8 and HSP90. *EMBO J.* 25 (20), 5015–5025.
- Ozes, O.N., Mayo, L.D., Gustin, J.A., Pfeffer, S.R., Pfeffer, L.M., Donner, D.B., 1999. NF-kappaB activation by tumor necrosis factor requires the Akt serine-threonine kinase. *Nature* 401 (6748), 82–85.
- Pearl, L.H., Prodromou, C., 2006. Structure and mechanism of HSP90 molecular chaperone machinery. *Ann. Rev. Biochem.* 75, 271–294.
- Powers, M.V., Workman, P., 2006. Targeting of multiple signaling pathways by heat shock protein 90 molecular chaperone inhibitors. *Endocrine-Related Cancer* 13, S125–S135.
- Rhoads, J.M., Corl, B.A., Harrel, R., Niu, X., Gatlin, L., Phillips, O., Blikslager, A., Moeser, A., Wu, G., Odle, J., 2007. Intestinal ribosomal p70(s6k) signaling is increased in piglet rotavirus enteritis. *Am. J. Physiol. Gastrointest. Liver Physiol.* 292, G913–G922.
- Rollo, E.E., Kumar, K.P., Reich, N.C., Cohen, J., Angel, J., Greenberg, H.B., Sheth, R., Anderson, J., Oh, B., Hempson, S.J., Mackow, E.R., Shaw, R.D., 1999. The epithelial cell response to rotavirus infection. *J. Immunol.* 163 (8), 4442–4452.
- Rossen, J.W.A., Bouma, J., Taatgeep, R.H.C., Buller, H.A., Einerhand, A.W.C., 2004. Inhibition of cyclooxygenase activity reduces rotavirus infection at a postbinding step. *J. Virol.* 78 (18), 9721–9730.
- Sausville, E.A., Tomaszewski, J.E., Ivy, P., 2003. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. *Curr. Cancer Drug Targets* 3, 377–383.
- Sedger, L., Ruby, J., 1994. Heat shock response to vaccinia virus infection. *J. Virol.* 68 (7), 4685–4689.
- Smith, E.M., Estes, M.K., Graham, D.Y., Gerba, C.P., 1979. A plaque assay for the simian rotavirus SA11. *J. Gen. Virol.* 43 (3), 513–519.
- Stebbins, C.E., Russo, A.A., Schneider, C., Rosen, N., Hartl, F.U., Pavletich, N.P., 1997. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. *Cell* 89 (2), 239–250.
- Sullivan, C.S., Pipas, J.M., 2001. The virus-chaperone connection. *Virology* 287 (1), 1–8.
- Sun, M., Fuentes, S.M., Timani, K., Sun, D., Murphy, C., Lin, Y., August, A., Teng, M.N., He, B., 2008. Akt plays a critical role in replication of nonsegmented negative-stranded RNA viruses. *J. Virol.* 82 (1), 105–114.
- Ujino, S., Yamaguchi, S., Shimotohno, K., Takaku, H., 2009. Heat-shock protein 90 is essential for stabilization of the hepatitis C virus non-structural protein NS3. *J. Biol. Chem.* 284 (11), 6841–6846.
- Welch, W.J., 1991. The role of heat-shock proteins as molecular chaperones. *Curr. Opin. Cell Biol.* 3 (6), 1033–1038.
- Yang, L., Dan, H.C., Sun, M., Liu, Q., Sun, X.M., Feldman, R.I., Hamilton, A.D., Polokoff, M., Nicosia, S.V., Herlyn, M., Sefti, S.M., Cheng, J.Q., 2004. Akt/protein kinaseB signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. *Cancer Res.* 64 (13), 4394–4399.
- Zhang, H., Burrows, F., 2004. Targeting multiple signal transduction pathways through inhibition of Hsp90. *J. Mol. Med.* 82 (8), 488–499.

## Effect of Osteopontin on Diarrhea Duration and Innate Immunity in Suckling Mice Infected with a Murine Rotavirus

Yoshimasa Maeno,<sup>1</sup> Masanori Shinzato,<sup>2</sup> Shigeo Nagashima,<sup>1</sup> Susan R. Rittling,<sup>3</sup> David T. Denhardt,<sup>4</sup> Toshimitsu Uede,<sup>5</sup> and Koki Taniguchi<sup>1</sup>

### Abstract

We studied the role of osteopontin (OPN) in host responses against rotavirus (RV) infection. OPN knockout (OPN-KO) suckling mice were more susceptible to RV (strain EW) infection and showed prolonged diarrhea duration compared to wild-type (WT) suckling mice. OPN in the small intestine of WT mice was expressed after 48 h post-infection. On day 2 postinfection, mRNA levels of interleukin-1 $\beta$ , tumor necrosis factor- $\alpha$ , and interleukin-15 in OPN-KO mice were lower than in WT mice, although mRNA expression of Th-1- and Th-2-related cytokines in the small intestine were nearly the same between OPN-KO and WT mice. These results suggested that OPN is involved in innate responses against RV infection.

### Introduction

**O**STEOPONTIN (OPN) IS A SIALATED PHOSPHOPROTEIN, categorized as an extracellular matrix protein (21). OPN is produced in injured or inflamed epithelium, endothelium, and smooth muscle cells, as well as activated lymphocytes, macrophages, and natural killer (NK) cells during inflammatory processes. In addition, OPN is detected in plasma, urine, and breast milk (2,18,21). OPN is involved in recruiting and stimulating macrophages and lymphocytes as host responses to pathogens (10,14,21). In infectious diseases such as herpes simplex virus type 1, *Listeria monocytogenes*, and *Plasmodium chabaudi chabaudi*, clearance of these pathogens in OPN-gene knockout (OPN-KO) mice was shown to be defective because of the deficiency of interleukin-12 (IL-12)- and interferon- $\gamma$  (IFN- $\gamma$ )-dependent T-helper-1 (Th-1) cell responses (2,16,18). These findings suggest that OPN is involved in innate immunity against those pathogens.

Rotavirus (RV) infection is the most important cause of severe acute gastroenteritis. Children with natural RV infection or suckling mice with experimental RV infection normally recover from acute gastroenteritis within 1 wk after disease onset. These findings suggest that innate immunity aids recovery from the disease. The importance of innate re-

sponses of the host has long been recognized because children in the acute stage of typical RV infection do not develop sufficient RV-specific T cells or antibodies that are needed to overcome infections (6,7,13,19,20). Regarding innate responses to RV infection, one study has recently demonstrated that OPN-KO mice with heterologous infection with a simian RV showed more intense and prolonged diarrhea than wild-type (WT) mice (25). The intestines of WT mice infected with RV exhibited marked increases in OPN mRNA expression and OPN protein secretion. These findings indicate that OPN modulates the severity of RV diarrhea; however, the role of innate immune responses through OPN has not been shown in RV infection (25). In this study, we examined the role of OPN in immune responses against RV infection using a model of homologous murine RV infection.

### Materials and Methods

For this study, culture-adapted murine RV strain EW (G3P[16]) provided by Dr. Yasutaka Hoshino of the National Institutes of Health was used for experimental infection. WT (OPN<sup>+/+</sup> C57BL/6, OPN allele a) mice were purchased from Japan SLC (Hamamatsu, Japan). OPN-KO (OPN<sup>-/-</sup>) mice (C57BL/6 $\times$ 129, C57BL/6 background, F6) were produced as

<sup>1</sup>Department of Virology and Parasitology, Fujita Health University School of Medicine, and <sup>2</sup>Department of Pathology, Fujita Health University School of Health Sciences, Toyoake, Aichi, Japan.

<sup>3</sup>The Forsyth Institute, Boston, Massachusetts.

<sup>4</sup>Department of Cell Biology and Neuroscience Division of Life Sciences, Rutgers University, Piscataway, New Jersey.

<sup>5</sup>Division of Molecular Immunology, Institute for Genetic Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.

described previously (23,24). All mice used in this study were bred in our facility. Mouse experiments were carried out according to the "Guidelines for the Management of Laboratory Animals at Fujita Health University." For RV infection, 6-day-old suckling mice were orally administered 100  $\mu$ L of serially diluted RV [ $1 \times 10^6$ ,  $1 \times 10^5$ ,  $1 \times 10^4$ ,  $1 \times 10^3$ , and  $1 \times 10^2$  plaque-forming units (PFU)/mL]. The plaques of strain EW were very small but clearly formed by using CV-1 cells and purified trypsin (T-0134; Sigma, St. Louis, MO). Each mouse was checked daily for diarrhea by gentle palpation of the abdomen for 10 d after infection. Stool consistency was evaluated on a three-point scale as follows: 1, normal; 2, mixed solid and liquid; and 3, liquid. Mice were sacrificed on days 0, 2, and 8 post-infection; the small intestines were removed, processed for mRNA analysis, and examined by light microscopy.

Total RNA in small intestinal cells was extracted using ISOGEN (Nippon Gene, Tokyo, Japan) based on the manufacturer's instructions. One microgram of isolated total RNA was reverse-transcribed to synthesize first-strand cDNA. The cDNA was subjected to PCR using specific oligonucleotide primers to amplify cDNAs encoding  $\beta$ -actin, OPN, and several cytokines, such as interleukin (IL)-12 p40, interferon (IFN)- $\gamma$ , IL-10, IL-1 $\beta$ , IL-15, and tumor necrosis factor (TNF)- $\alpha$ . PCR reactions were performed as previously described (15,16). The primer sequences were as follows:  $\beta$ -actin: sense 5'-CCA GAG CAA GAG AGG TAT CC-3', antisense 5'-AGT CTA GAG CAA CAT AGC ACA G-3'; OPN: sense 5'-ATG AGA TTG GCA GTG ATT TG-3', antisense 5'-GTT GAC CTC AGA AGA TGA AC-3'; IL-12 p40: sense 5'-ATG GCC ATG TGG GAG CTG GAG-3', antisense 5'-TTT GGT GCT TCA CAC TTC AGG-3'; IFN- $\gamma$ : sense 5'-CAT TGA AAG CCT AGA AAG TCT G-3', antisense 5'-CTC ATG GAA TGC ATC CTT TTT CG-3'; IL-10: sense 5'-CCA GTT TTA CCT GGT AGA AGT GAT G-3', antisense 5'-TGT CTA GGT CCT GGA GTC CAG CAG ACT CAA-3'; IL-1 $\beta$ : sense 5'-AGC TTC CTT GTG CAA GTG TC-3', antisense 5'-CAC ACC AGC AGG TTA TCA TC-3'; IL-15: sense 5'-TCC ATC TCG TGC TAC TTG TGT TTC C-3', antisense 5'-TCT TAC ATC TAT CCA GTT GGC CTC T-3'; and TNF- $\alpha$ : sense 5'-AAC TAG TGG TGC CAG CCG AT-3', antisense 5'-CTT CAC AGA GCA ATG ACT CC-3'. PCR products were separated by electrophoresis on a 1.5% agarose gel and stained with ethidium bromide. The gels were then photographed, and the densities of the DNA bands were determined with Lane & Spot Analyzer software (Atto, Tokyo, Japan). Expression data of the target mRNAs of cytokines and OPN were standardized by quantification of  $\beta$ -actin mRNA as an internal control.

To examine for the presence of OPN in the small intestines, an avidin-biotin peroxidase complex (ABC) method was applied to paraffin-embedded small intestinal tissues. We used anti-mouse OPN (2.2) rat IgG monoclonal antibody (Immuno-Biological Laboratories, Gunma, Japan), and biotinylated anti-rat IgG (H+L) goat IgG (Immuno-Biological Laboratories) as the primary and secondary antibodies, respectively. ABC complex (Vector Laboratories Inc., Burlingame, CA) and diaminobenzidine tetrahydrochloride (Sigma) were used to develop the reaction.

Statistical evaluation was performed with the Mann-Whitney test (two-tailed). All analyses were performed using SPSS software (SPSS Japan, Tokyo, Japan), with a value of  $p < 0.05$  being considered significant.

## Results and Discussion

In order to investigate the effect of OPN on RV infection, WT and OPN-KO suckling mice were orally administered serially diluted murine RV strain EW ( $1 \times 10^6$ ,  $1 \times 10^5$ ,  $1 \times 10^4$ ,  $1 \times 10^3$ , and  $1 \times 10^2$  PFU), and the duration of diarrhea was monitored. WT mice presented with diarrhea when administered a dose of more than  $1 \times 10^4$  PFU of RV, whereas OPN-KO mice presented with diarrhea at a dose of ten times lower concentration than that needed in WT suckling mice (Fig. 1). The durations of diarrhea of WT mice infected with  $1 \times 10^6$ ,  $1 \times 10^5$ , and  $1 \times 10^4$  PFU of RV were 5, 4, and 4 d, respectively. In contrast, those of OPN-KO mice infected with  $1 \times 10^6$ ,  $1 \times 10^5$ ,  $1 \times 10^4$ , and  $1 \times 10^3$  PFU of RV were 8, 8, 8, and 6 days, respectively (Fig. 1). The onset day of diarrhea in WT mice after RV infection with the same doses (except  $1 \times 10^6$  PFU of RV) was later than that of OPN-KO mice. Similarly, the positive rate of diarrhea in WT mice was lower than that seen in OPN-KO mice (Fig. 1); however, the diarrhea scores showed no significant difference between OPN-KO and WT mice (data not shown).




FIG. 1. Susceptibility to rotavirus infection and rotavirus-induced diarrheal period in WT and OPN-KO suckling mice. Six-day-old suckling mice were orally administered 100  $\mu$ L of serially diluted RV ( $1 \times 10^6$ ,  $1 \times 10^5$ ,  $1 \times 10^4$ ,  $1 \times 10^3$ , and  $1 \times 10^2$  PFU/mL). Results were obtained with 12–20 mice per group in two independent experiments using 6–10 mice per group.




FIG. 2. Micrographs of small intestinal tissues from WT (a–f) and OPN-KO (g–j) mice infected with RV. On day 2, the small intestines from WT (c) and OPN-KO (g) mice showed intracytoplasmic vacuolar degeneration of epithelial cells and thinning of the striated border compared with day 0 (a). On day 8 post-infection (e and i), both types of mice showed improvement in the intestinal villi related to regeneration of epithelial cells. In ABC staining for OPN, WT mice (d) showed positive reactions in the striated border (arrows), goblet cells (arrowheads), and monocytes/macrophages (white arrows) in the small intestine on day 2, although this was not observed on day 0 (b). On day 8 (f), the striated border (arrows) and goblet cells (arrowhead) showed a slightly positive reaction. OPN-KO mice (h and j) showed negative reactions on days 2 and 8 (a, c, e, g, and i were stained with hematoxylin and eosin; b, d, f, h and j were stained with avidin-biotin peroxidase complex for OPN; bars represent 100  $\mu$ m for a, c, e, g, and i, and 50  $\mu$ m for b, d, f, h, and j).

In light microscopic examinations, the small intestines of both OPN-KO and WT mice on day 2 after RV inoculation ( $1 \times 10^6$  PFU) showed intracytoplasmic vacuolar degeneration of epithelial cells and thinning of the striated border (Fig. 2c and g) compared with before infection (D0) (Fig. 2a). The inherent mucosal layer of OPN-KO mice was more markedly influenced than that of WT mice. On day 2 post-infection, infiltration of inflammatory cells, such as lymphocytes, neutrophils, eosinophils, and monocytes/macrophages, was observed in the inherent mucosal layer in WT mice (Fig. 2c), but not in OPN-KO mice (Fig. 2g). On day 8 post-infection, improvement in the intestinal villi related to the regeneration of epithelial cells was marked in OPN-KO mice (Fig. 2i), whereas the improvement was delayed in WT mice (Fig. 2e). Concerning the infiltration of inflammatory cells in WT mice, slight infiltration of lymphocytes was observed in some mice, while infiltration of eosinophils persisted in the remaining mice (Fig. 2e); however, no infiltration was seen in OPN-KO mice (Fig. 2i).




FIG. 3. Expression of OPN mRNA in small intestines from WT and OPN-KO mice on day 0 (before infection) and on days 2 and 8 after RV infection. OPN mRNA was measured by semi-quantitative RT-PCR. Data are standardized by quantification of  $\beta$ -actin mRNA used as an internal control. The bar represents the mean  $\pm$  SEM of the results of 10 mice per group in two independent experiments using 5 mice per group.